
<html lang="en"     class="pb-page"  data-request-id="2fa0f8aa-a3d2-4e20-9273-c3c7f24b71bf"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/jm901146p;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2009.52.issue-21;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of A Novel Her-1/Her-2 Dual Tyrosine Kinase Inhibitor for the Treatment of Her-1 Selective Inhibitor-Resistant Non-small Cell Lung Cancer" /></meta><meta name="dc.Creator" content="Mi Young  Cha" /></meta><meta name="dc.Creator" content="Kwang-Ok  Lee" /></meta><meta name="dc.Creator" content="Jong Woo  Kim" /></meta><meta name="dc.Creator" content="Chang Gon  Lee" /></meta><meta name="dc.Creator" content="Ji Yeon  Song" /></meta><meta name="dc.Creator" content="Young Hoon  Kim" /></meta><meta name="dc.Creator" content="Gwan Sun  Lee" /></meta><meta name="dc.Creator" content="Seung Bum  Park" /></meta><meta name="dc.Creator" content="Maeng Sup  Kim" /></meta><meta name="dc.Description" content="A novel series of (S)-1-acryloyl-N-[4-(arylamino)-7-(alkoxy)quinazolin-6-yl]pyrrolidine-2-carboxamides were synthesized and evaluated as Her-1/Her-2 dual inhibitors. In contrast to the Her-1 select..." /></meta><meta name="Description" content="A novel series of (S)-1-acryloyl-N-[4-(arylamino)-7-(alkoxy)quinazolin-6-yl]pyrrolidine-2-carboxamides were synthesized and evaluated as Her-1/Her-2 dual inhibitors. In contrast to the Her-1 select..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 15, 2009" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm901146p" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2009 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm901146p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm901146p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm901146p" /></link>
        
    
    

<title>Discovery of A Novel Her-1/Her-2 Dual Tyrosine Kinase Inhibitor for the Treatment of Her-1 Selective Inhibitor-Resistant Non-small Cell Lung Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm901146p" /></meta><meta property="og:title" content="Discovery of A Novel Her-1/Her-2 Dual Tyrosine Kinase Inhibitor for the Treatment of Her-1 Selective Inhibitor-Resistant Non-small Cell Lung Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0009.jpeg" /></meta><meta property="og:description" content="A novel series of (S)-1-acryloyl-N-[4-(arylamino)-7-(alkoxy)quinazolin-6-yl]pyrrolidine-2-carboxamides were synthesized and evaluated as Her-1/Her-2 dual inhibitors. In contrast to the Her-1 selective inhibitors, our novel compounds are irreversible inhibitors of Her-1 and Her-2 tyrosine kinases with the potential to overcome clinically relevant, mutation-induced drug resistance. The selected compounds (19c, 19d) showed excellent EGFR inhibition activity even toward the T790M mutation of Her-1 tyrosine kinase with excellent selectivity. The excellent pharmacokinetic profiles of these compounds in rats and their robust in vivo efficacy in an A431 xenograft model clearly demonstrate that they merit further investigation as novel therapeutic agents for EGFR-targeting treatment of solid tumors, especially Her-1 selective inhibitor-resistant non-small cell lung cancer." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm901146p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm901146p">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm901146p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm901146p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm901146p&amp;href=/doi/10.1021/jm901146p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2009</span><span class="cit-fg-volume">, 52</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 6880-6888</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/52/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm901145s" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm901153x" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of A Novel Her-1/Her-2 Dual Tyrosine Kinase Inhibitor for the Treatment of Her-1 Selective Inhibitor-Resistant Non-small Cell Lung Cancer</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mi+Young++Cha">Mi Young Cha</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kwang-Ok++Lee">Kwang-Ok Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jong+Woo++Kim">Jong Woo Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chang+Gon++Lee">Chang Gon Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ji+Yeon++Song">Ji Yeon Song</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Young+Hoon++Kim">Young Hoon Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gwan+Sun++Lee">Gwan Sun Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Seung+Bum++Park">Seung Bum Park</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maeng+Sup++Kim">Maeng Sup Kim</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon, Hwaseong, Gyeonggi-do, 445-813, Korea</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Chemistry, Seoul National University</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department of Biophysics and Chemical Biology, Seoul National University, Seoul 151-747, Korea</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: +82-31-3715100 (M.S.K.); +82-2-880-9090 (S.B.P.). Fax: +82-31-3715068 (M.S.K.); +82-2-884-4025 (S.B.P.). E-mail: <a href="/cdn-cgi/l/email-protection#365d5f5b45765e57585b5f185559185d44"><span class="__cf_email__" data-cfemail="1c7775716f5c747d727175327f7332776e">[email protected]</span></a> (M.S.K.); <a href="/cdn-cgi/l/email-protection#5221302233203912213c277c33317c3920"><span class="__cf_email__" data-cfemail="d8abbaa8b9aab398abb6adf6b9bbf6b3aa">[email protected]</span></a> (S.B.P.).</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm901146p&amp;href=/doi/10.1021%2Fjm901146p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2009</span></span><span class="cit-volume">, 52</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 6880–6888</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 15, 2009</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 July 2009</li><li><span class="item_label"><b>Published</b> online</span>15 October 2009</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 November 2009</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm901146p" title="DOI URL">https://doi.org/10.1021/jm901146p</a></div><div class="article_header-article-copyright"><strong>Copyright © 2009 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6880%26pageCount%3D9%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMi%2BYoung%2BCha%252C%2BKwang-Ok%2BLee%252C%2BJong%2BWoo%2BKim%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D52%26issueNum%3D21%26contentID%3Djm901146p%26title%3DDiscovery%2Bof%2BA%2BNovel%2BHer-1%252FHer-2%2BDual%2BTyrosine%2BKinase%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BHer-1%2BSelective%2BInhibitor-Resistant%2BNon-small%2BCell%2BLung%2BCancer%26numPages%3D9%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6888%26publicationDate%3DNovember%2B2009">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm901146p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3235</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">29</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm901146p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of A Novel Her-1/Her-2 Dual Tyrosine Kinase Inhibitor for the Treatment of Her-1 Selective Inhibitor-Resistant Non-small Cell Lung Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mi&quot;,&quot;last_name&quot;:&quot;Young Cha&quot;},{&quot;first_name&quot;:&quot;Kwang-Ok&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Jong&quot;,&quot;last_name&quot;:&quot;Woo Kim&quot;},{&quot;first_name&quot;:&quot;Chang&quot;,&quot;last_name&quot;:&quot;Gon Lee&quot;},{&quot;first_name&quot;:&quot;Ji&quot;,&quot;last_name&quot;:&quot;Yeon Song&quot;},{&quot;first_name&quot;:&quot;Young&quot;,&quot;last_name&quot;:&quot;Hoon Kim&quot;},{&quot;first_name&quot;:&quot;Gwan&quot;,&quot;last_name&quot;:&quot;Sun Lee&quot;},{&quot;first_name&quot;:&quot;Seung&quot;,&quot;last_name&quot;:&quot;Bum Park&quot;},{&quot;first_name&quot;:&quot;Maeng&quot;,&quot;last_name&quot;:&quot;Sup Kim&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2009&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;52&quot;,&quot;pages&quot;:&quot;6880-6888&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm901146p&quot;},&quot;abstract&quot;:&quot;A novel series of (S)-1-acryloyl-N-[4-(arylamino)-7-(alkoxy)quinazolin-6-yl]pyrrolidine-2-carboxamides were synthesized and evaluated as Her-1/Her-2 dual inhibitors. In contrast to the Her-1 selective inhibitors, our novel compounds are irreversible inhibitors of Her-1 and Her-2 tyrosine kinases with the potential to overcome clinically relevant, mutation-induced drug resistance. The selected compounds (19c, 19d) showed excellent EGFR inhibition activity even toward the T790M mutation of Her-1 tyrosine kinase with excellent selectivity. The excellent pharmacokinetic profiles of these compounds in rats and their robust in vivo efficacy in an A431 xenograft model clearly demonstrate that they merit further investigation as novel therapeutic agents for EGFR-targeting treatment of solid tumors, especially Her-1 selective inhibitor-resistant non-small cell lung cancer.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901146p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901146p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901146p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901146p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm901146p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901146p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm901146p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm901146p&amp;href=/doi/10.1021/jm901146p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm901146p" /></input><a href="/doi/pdf/10.1021/jm901146p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm901146p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm901146p%26sid%3Dliteratum%253Aachs%26pmid%3D19888761%26genre%3Darticle%26aulast%3DCha%26date%3D2009%26atitle%3DDiscovery%2Bof%2BA%2BNovel%2BHer-1%252FHer-2%2BDual%2BTyrosine%2BKinase%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BHer-1%2BSelective%2BInhibitor-Resistant%2BNon-small%2BCell%2BLung%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D52%26issue%3D21%26spage%3D6880%26epage%3D6888%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/52/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A novel series of (<i>S</i>)-1-acryloyl-<i>N</i>-[4-(arylamino)-7-(alkoxy)quinazolin-6-yl]pyrrolidine-2-carboxamides were synthesized and evaluated as Her-1/Her-2 dual inhibitors. In contrast to the Her-1 selective inhibitors, our novel compounds are irreversible inhibitors of Her-1 and Her-2 tyrosine kinases with the potential to overcome clinically relevant, mutation-induced drug resistance. The selected compounds (<b>19c</b>, <b>19d</b>) showed excellent EGFR inhibition activity even toward the T790M mutation of Her-1 tyrosine kinase with excellent selectivity. The excellent pharmacokinetic profiles of these compounds in rats and their robust in vivo efficacy in an A431 xenograft model clearly demonstrate that they merit further investigation as novel therapeutic agents for EGFR-targeting treatment of solid tumors, especially Her-1 selective inhibitor-resistant non-small cell lung cancer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51807" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51807" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A signaling cascade of epidermal growth factor receptors (EGFRs<a class="ref internalNav" href="#fn1" aria-label="a">a</a>), which is composed of four members, Her-1 (ErbB-1), Her-2 (neu, ErbB-2), Her-3 (ErbB-3), and Her-4 (ErbB-4), plays a key role in regulating cell proliferation and differentiation in many tissue types.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> Therefore, dysregulation of the EGFR signaling pathway may contribute to malignant transformation, and overexpression of Her-1 and Her-2 is frequently observed in several solid tumors.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Accordingly, the EGFR family is a major target of anticancer agents.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a><div class="NLM_fn" id="fn1">a<p class="last">Abbreviations: Her, human epidermal growth factor receptor; EGFR, epidermal growth factor receptor.</p></div></div><div class="NLM_p">Several small-molecule inhibitors of EGFR tyrosine kinases have been developed (see Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The first class of EGFR-targeting therapeutic agents includes the Her-1 specific inhibitors, <b>1</b> (Gefitinib)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and <b>2</b> (Erlotinib),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> for treatment of non-small cell lung cancer. However, the drug’s resistance to Her-1 specific inhibitors has been clinically observed and has been associated with the T790M mutation of Her-1 tyrosine kinase.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The second class includes the Her-1/Her-2 dual inhibitor, <b>3</b> (Lapatinib),<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> for treatment of Her-2-positive breast cancer. Because Her-1 tyrosine kinase binds Her-1 or Her-2 tyrosine kinases to form a homo- or heterodimer for the signal transduction in EGFR signaling cascade, Her-1/Her-2 dual inhibition is more effective than just Her-1 inhibition.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The third class includes the EGFR irreversible inhibitors, <b>4</b> (HKI-272)<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> and <b>5</b> (CI-1033).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Among these classes of EGFR inhibitors, <b>4</b> and <b>5</b> drew our attention because of their interesting mode of action; that is, inhibition of EGFR tyrosine kinases through irreversible modification of a Cys residue (Cys773 of Her-1 and Cys805 of Her-2) at their respective active sites. It has recently been reported that irreversible inhibition of EGFR tyrosine kinases can be a more advantageous approach because these agents may be able to overcome accumulating resistance toward the reversible inhibitors, such as <b>1</b> and <b>2</b>, associated with clinically frequent T790M mutation of Her-1 tyrosine kinase in response to drug treatment.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19">(15-19)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative inhibitors of EGFR tyrosine kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50130" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50130" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemical Design and Synthesis</h3><div class="NLM_p">To develop novel EGFR-targeting therapeutic agents with enhanced potency that can overcome the drug resistance of the Her-1 specific agents, we pursued the synthesis of novel core skeletons inspired by irreversible EGFR inhibitors. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>, the <i>N</i>-acryloyl moiety is commonly shared among the irreversible EGFR inhibitors and is responsible for the covalent modification of the Cys residue at the active site of the EGFR tyrosine kinases. Our previous experience also confirmed the importance of aryl-substituted 4-aminoquinazoline as a key moiety for specific binding at the ATP-binding site of the EGFR tyrosine kinases. Therefore, we hypothesized that proper orientation and distance between the acrylamides and the 4-aminoquinazoline moieties are essential for selective EGFR inhibitors. In particular, we were interested in the introduction of various linkers with limited conformational flexibility. Through extensive research, we identified novel 4-aminoquinazoline with <i>N</i>-acryl cyclic unnatural amino acids as potential candidates. Herein, we wish to report our efforts toward the identification of acryloyl-<i>N</i>-[4-(arylamino)quinazolin-6-yl]carboxamides as new Her-1/Her-2 dual inhibitors (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of novel Her-1/Her-2 dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of the acryloyl-<i>N</i>-[4-(arylamino)quinazolin-6-yl]carboxamide analogs <b>12</b> is outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. The reaction sequence was initiated using commercially available 2-amino-5-nitrobenzoic acid <b>6</b> at an elevated temperature with formamide as a solvent to yield 6-nitroquinazolinone <b>7</b>, followed by its chlorination using excessive thionyl chloride and phosphoryl chloride in the presence of a catalytic amount of DMF for preparation of 4-chloroquinazoline <b>8</b> with a high yield. The resulting 4-chloroquinazoline <b>8</b> was treated with aniline derivatives in refluxing isopropyl alcohol to provide 4-anilino-6-nitroquinazoline <b>9</b> with a quantitative yield. After simple filtration of the HCl salts of <b>9</b>, key intermediates, <i>N</i>-4-aryl-substituted 4-anilino-6-aminoquinazolines <b>10</b>, were obtained through reduction of <b>9</b> with iron powder in concd HCl. Cyclic amino acid linkers were then introduced at the 6-amino group of <b>10</b> through EDCI-mediated amide coupling with various <i>N</i>-Boc-protected cyclic amino acids, such as azetidine carboxylic acid, <span class="smallcaps smallerCapital">l</span>-proline, and piperidine carboxylic acid. Subsequently, the Boc protecting group was removed by treatment with 30% trifluoroacetic acid in DCM to yield quinazoline derivatives <b>11</b>. Finally, EDCI-mediated amide coupling of <b>11</b> with acrylic acid provided the desired acryloyl-<i>N</i>-[4-(arylamino) quinazolin-6-yl]carboxamide analogs <b>12</b> with 14.6% overall yield.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) formamide, 170 °C; (b) SOCl<sub>2</sub>, POCl<sub>3</sub>, DMF (cat.), reflux; (c) anilines, <i>i</i>-PrOH, reflux; (d) Fe, concd HCl (cat.), 50% EtOH, reflux; (e) <i>N</i>-Boc-amino acids, EDCI, pyridine, r.t.; (f) TFA, DCM, r.t.; (g) acrylic acid, EDCI, pyridine, THF, 0 °C.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Biological Effect of the Structures of Carboxamides and Quinazolines Having Various Linker Moieties with Restricted Conformational Flexibility</h3><div class="NLM_p">All synthesized analogs were initially tested for their ability to inhibit cellular proliferation in two representative EGFR-positive cell lines: A431 (Her-1-overexpressing human vaginal epidermoid cancer cell line)<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and SK-Br3 (Her-2-overexpressing human breast cancer cell line).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The orientation of the acrylamide moiety, based on various substituents in the carboxamide moiety of the cyclic amino acids at the C<sub>6</sub> position of the quinazoline core skeleton. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, the 1-acryloyl-2-carboxamide derivatives of azetidine (<b>13a</b>), pyrrolidine (<b>13c</b>), and piperidine (<b>13e</b>) at the C<sub>6</sub> position of the quinazolines had stronger potency in the A431 cell-based proliferation assay compared to the 1-acryloyl-3-carboxamide derivatives of azetidine (<b>13b</b>; entries 1 and 2, IC<sub>50</sub> = 218 vs 1400 nM), pyrrolidine (<b>13d</b>; entries 3 and 4, IC<sub>50</sub> = 32 vs 350 nM), and piperidine (<b>13f</b>; entries 5 and 6, IC<sub>50</sub> = 105 vs 286 nM). In addition, the 1-acryloyl-piperidine-4-carboxamide derivative <b>13g</b> (IC<sub>50</sub> = 513 nM) had diminished potency compared to <b>13e</b> and <b>13f</b> (entries 5−7). A similar pattern of effects associated with substitution of conformationally rigid linkers at the C<sub>6</sub> position of quinazoline was also observed in the SK-Br3 cell-based proliferation assay; the 1-acryloyl-2-carboxamide derivatives of azetidine (<b>13a</b>), pyrrolidine (<b>13c</b>), and piperidine (<b>13e</b>) at the C<sub>6</sub> position of quinazoline had stronger potency compared to the 1-acryloyl-3-carboxamide derivatives of azetidine (<b>13b</b>; entries 1 and 2, IC<sub>50</sub> = 13 vs 59 nM), pyrrolidine (<b>13d</b>; entries 3 and 4, IC<sub>50</sub> = 10 vs 49 nM), and piperidine (<b>13f</b>; entries 5 and 6, IC<sub>50</sub> = 14 vs 39 nM); furthermore, the 1-acryloyl-piperidine-4-carboxamide <b>13g</b> had diminished potency (IC<sub>50</sub> = 71 nM) compared to <b>13e</b> and <b>13f</b> (entries 5−7). Potency was also influenced by the stereochemistry of the cyclic amino acids; stronger potency was observed with <span class="smallcaps smallerCapital">l</span>-proline (entry 3) than with <span class="smallcaps smallerCapital">d</span>-proline (entry 8) as linker moieties with conformational rigidity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Cellular Activity<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a>of Synthesized Analogs <b>13</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0001.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table single-image frame_bottom"><colgroup><col /></col></colgroup><tbody><tr valign="top"><td><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0002.gif" alt="" id="fx2" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">All biological data are mean values for three independent experiments performed in duplicate.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">A431 is Her-1-overexpressing human vaginal epidermoid cancer cell line.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">SK-Br3 is Her-2-overexpressing human breast cancer cell line.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last"><b>3</b> (Lapatinib) was synthesized using the synthetic protocol of WO99/35146.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Synthesis and Biological Evaluation of Analogs with C<sub>4</sub>- and C<sub>7</sub>-Modification of Quinazoline</h3><div class="NLM_p">After optimization of the cyclic linker moiety for proper orientation of the Cys-capturing acrylamide moiety at the C<sub>6</sub> position, we turned our attention to the C<sub>4</sub> and C<sub>7</sub> positions of the quinazoline core skeleton to improve potency. Introduction of substituents such as methoxy and methoxyethyloxy at the C<sub>7</sub> position was pursued with the optimized moiety, <i>N</i>-acryloyl-<span class="smallcaps smallerCapital">l</span>-proline, at the C<sub>6</sub> position of 6-aminoquinazoline. Systematic replacement of 3-chloro-4-(pyridin-2-ylmethoxy) aniline with various 2, 3, or 4-halogen-substituted anilines was also conducted; notably, 4-fluoro-3-chloroaniline is a moiety shared between <b>1</b> (Gefitinib) and <b>5</b> (CI-1033). 4-Anilino-7-fluoro-6-nitroquinazolines <b>15</b> were prepared according to the modified protocol shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, beginning with 2-amino-4-fluoro-5-nitrobenzoic acid <b>14</b>, followed by treatment with either sodium methoxide or 2-methoxyethanol to yield the C<sub>4</sub>- and C<sub>7</sub>-modified key intermediates <b>16</b> and <b>17</b> (see Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). The final products with C<sub>4</sub>- and C<sub>7</sub>-modifications (<b>18</b> and <b>19</b>) were prepared from intermediates <b>16</b> and <b>17</b> using a process identical to that shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) formamide, 170 °C; (b) SOCl<sub>2</sub>, POCl<sub>3</sub>, DMF (cat.), reflux; (c) anilines, <i>i</i>-PrOH, reflux; (d) sodium methoxide, DMSO, r.t.; (e) 2-methoxyethanol, KOTMS, DMSO, r.t.</p></p></figure><div class="NLM_p">The resulting analogs <b>18</b> and <b>19</b> were subjected to cellular growth inhibition assays using the Her-1-positive A431 cell line and the Her-2-positive SK-Br3 cell line. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, replacement of 3-chloro-4-(pyridin-2-ylmethoxy)aniline at the C<sub>4</sub> position of quinazoline (<b>18a</b>) with halogen-substituted anilines (<b>18b</b>−<b>d</b>) in the C<sub>7</sub>-methoxy analogs <b>18</b> substantially reduced growth inhibition activity against SK-Br3 (IC<sub>50</sub> = 3 vs 64, 33, and 322 nM, <b>18a</b>−<b>d</b>, respectively). A similar pattern of reduced activities (1.4- to 2.6-fold, <b>18c</b> and <b>18d</b> compared to <b>18a</b>, respectively) was observed in the Her-1-positive A431 cell proliferation assay, except for the C<sub>4</sub> modification with 4-fluoro-3-chloroaniline derivative <b>18b</b>. On the other hand, replacement of 3-chloro-4-(pyridin-2-ylmethoxy) aniline (<b>19a</b>) with halogen-substituted anilines (<b>19b</b>−<b>f</b>) at the C<sub>4</sub> position in the C<sub>7</sub>-methoxyethyloxy analogs <b>19</b> resulted in 1.3- to 3.8-fold enhancement of cellular activities in the A431 assay, but 2.3- to 7-fold reduction of cellular activities in the SK-Br3 assay. Even though the activity reduction in <b>19c</b>, <b>19d</b>, and <b>19e</b> compared to <b>19a</b> was observed against SK-Br3 (IC<sub>50</sub> = 3 vs 8, 7, and 9 nM, <b>19a</b>, <b>19c</b>−<b>e</b>, respectively), the selected C<sub>7</sub>-methoxyethyloxy analogs (<b>19c</b>−<b>e</b>) showed high cellular activities in the SK-Br3 assay (IC<sub>50</sub> < 10 nM).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Cellular Activity<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> of Synthesized Analogs <b>18</b> and <b>19</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0004.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table single-image frame_bottom"><colgroup><col /></col></colgroup><tbody><tr valign="top"><td><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0005.gif" alt="" id="fx4" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">All biological data are mean values for three independent experiments performed in duplicate.</p></div></div></div><div class="NLM_p">Based on the results of the cellular growth inhibition assays with the Her-1-positive A431 and the Her-2-positive SK-Br3 cell lines, we selected compounds <b>19c</b> and <b>19d</b> for further biological evaluation as potential EGFR-targeting therapeutic agents. First, we conducted an enzyme-based inhibition assay with Her-1 and Her-2 tyrosine kinases. In particular, we used a <b>1</b> (Gefitinib)- and <b>2</b> (Erlotinib)-resistant T790M mutation of Her-1 tyrosine kinase to include drug resistance to these therapeutic agents. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, <b>19c</b> and <b>19d</b> demonstrated strong inhibition activities against Her-1/Her-2 kinase than <b>3</b> (Lapatinib), and <b>19c</b> and <b>19d</b> also demonstrated excellent potency toward the T790M mutation of Her-1 tyrosine kinase. The additional fluorine at the <i>para</i>-position of the C<sub>4</sub>-aniline (<b>19d</b>) enhanced its potency in the enzymatic inhibition assay as compared to compound <b>19c</b>. This conclusion was confirmed by the results of the cell-based proliferation assay. In addition to Her-1-positive A431 and Her-2-positive SK-Br3, we tested <b>19c</b> and <b>19d</b> with H1975, an <b>1</b> (Gefitinib)/<b>2</b> (Erlotinib)-resistant non-small cell lung cancer cell line that harbors the T790 M and L858R mutations.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> This biological evaluation clearly demonstrated that our novel therapeutic agents <b>19c</b> and <b>19d</b>, have excellent potency as a Her-1/Her-2 dual inhibitor and can overcome clinically frequent drug resistance, having demonstrated strong enzymatic inhibition activity against <b>1</b> (Gefitinib)/<b>2</b> (Erlotinib)-resistant (T790M) Her-1 tyrosine kinase (<b>19c</b>, IC<sub>50</sub> = 24 nM and <b>19d</b>, IC<sub>50</sub> = 11 nM) and in vitro cellular activity against the <b>1</b> (Gefitinib)/<b>2</b> (Erlotinib)-resistant cancer cell line H1975 (<b>19c</b>, IC<sub>50</sub> = 213 nM and <b>19d</b>, IC<sub>50</sub> = 63 nM). But <b>19c</b> and <b>19d</b> did not show growth inhibitory activity against normal cell line, Hs27 (<b>19c</b>, IC<sub>50</sub> = 6603 nM and <b>19d</b>, IC<sub>50</sub> = 7442 nM). Next, we checked the selectivity profile of <b>19c</b> and <b>19d</b> against a panel of 25 kinases including receptor tyrosine kinases, cytoplasmic tyrosine kinases, and serine/threonine kinases. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, our leading compound <b>19c</b> showed excellent activities (IC<sub>50</sub> < 0.1 μM) against EGFR tyrosine kinases (Her-1, -2, and -4) with superb selectivity. But, we observed some cross-activities (IC<sub>50</sub> < 0.1 μM) in the case of <b>19d</b> against Ret, Lck, Abl1, and Src. Lastly, we tested the mode of action of <b>19c</b> using an A431 cell washout experiment. The phosphorylation rate of EGFR after medium washout was measured using Western blot analysis. After 8 h of medium washout, only 15% of EGFR was phosphorylated when A431 cells were treated with <b>19c</b>. In comparison, <b>2</b> (Erlotinib)-treated cells restored their 100% phosphorylation on EGFR in 8 h after medium washout. The significant reduction in the phosphorylation rate of EGFR suggests that our novel therapeutic agent <b>19c</b> has an irreversible binding mode of action toward EGFR.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Enzymatic and Cellular Activities<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a>of the Synthesized Analogs <b>19c</b> and <b>19d</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="justify" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th align="center"> </th><th class="rowsep1" colspan="3" align="center">enzyme assay, IC<sub>50</sub> (nM)</th><th class="rowsep1" colspan="4" align="center">cell assay, IC<sub>50</sub> (nM)</th></tr><tr valign="top"><th align="center">compound</th><th align="center">Her-1</th><th align="center">Her-2</th><th align="center">Her-1 T790M</th><th align="center">A431</th><th align="center">SK-Br3</th><th align="center">H1975<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th align="center">Hs27<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top"><td align="left"><b>19c</b></td><td align="left">13</td><td align="left">42</td><td align="left">24</td><td align="justify">8</td><td align="left">8</td><td align="left">213</td><td align="left">6603</td></tr><tr valign="top" class="rowsep1"><td class="rowsep1" align="left"><b>19d</b></td><td class="rowsep1" align="left">9</td><td class="rowsep1" align="left">18</td><td class="rowsep1" align="left">11</td><td class="rowsep1" align="justify">7</td><td class="rowsep1" align="left">7</td><td class="rowsep1" align="left">63</td><td class="rowsep1" align="left">7442</td></tr><tr valign="top"><td align="left"><b>3</b> (lapatinib)</td><td align="left">52</td><td align="left">36</td><td align="left">>1000</td><td align="justify">104</td><td align="left">29</td><td align="left">>1000</td><td align="left">>10000</td></tr><tr valign="top"><td align="left"><b>2</b> (erlotinib)</td><td align="left">>1000<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td align="left">>1000</td><td align="left">>1000</td><td align="justify">96<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td align="left">>1000</td><td align="left">>1000</td><td align="left">>10000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">All biological data are mean values for three independent experiments performed in duplicate.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">H1975 is an <b>1</b> (Gefitinib)/<b>2</b> (Erlotinib)-resistant non-small cell lung cancer cell line that harbors the T790 M and L858R mutations.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Hs27 is a normal human foreskin cell line.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Reported activities in reference, IC<sub>50</sub> 2 nM against Her-1 [<i>Cancer Research</i><b>1997</b>, <i>57</i> (21), 4838] and IC<sub>50</sub> 1.5 μM against A431 [<i>Proc. Am. Assoc. Cancer Res.</i><b>2005</b>, <i>46</i>, Abstract #1670].</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Selectivity Profile of Synthesized Analogs <b>19c</b> and <b>19d</b> against 25 Kinases<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th align="left">IC<sub>50</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a> (μM)</th><th align="left"><b>19c</b></th><th align="left"><b>19d</b></th></tr></thead><tbody><tr valign="top"><td colspan="3" align="left">Receptor Tyrosine Kinase</td></tr><tr valign="top"><td align="left">Her-1</td><td align="left"><0.1</td><td align="left"><0.1</td></tr><tr valign="top"><td align="left">Her-2</td><td align="left"><0.1</td><td align="left"><0.1</td></tr><tr valign="top"><td align="left">Her-4</td><td align="left"><0.1</td><td align="left"><0.1</td></tr><tr valign="top"><td align="left">Flt-1</td><td align="left">>10.0</td><td align="left">10.0</td></tr><tr valign="top"><td align="left">KDR</td><td align="left">1.3</td><td align="left">0.6</td></tr><tr valign="top"><td align="left">Flt-4</td><td align="left">2.7</td><td align="left">4.5</td></tr><tr valign="top"><td align="left">Flt-3</td><td align="left">>10.0</td><td align="left">>10.0</td></tr><tr valign="top"><td align="left">PDGFRα</td><td align="left">>10.0</td><td align="left">>10.0</td></tr><tr valign="top"><td align="left">PDGFRβ</td><td align="left">>10.0</td><td align="left">>10.0</td></tr><tr valign="top"><td align="left">IGF-1R</td><td align="left">>10.0</td><td align="left">>10.0</td></tr><tr valign="top"><td align="left">Kit</td><td align="left">>10.0</td><td align="left">>10.0</td></tr><tr valign="top"><td align="left">FGFR1</td><td align="left">>10.0</td><td align="left">>10.0</td></tr><tr valign="top"><td align="left">FGFR2</td><td align="left">4.1</td><td align="left">2.0</td></tr><tr valign="top"><td align="left">Ret</td><td align="left">0.7</td><td align="left"><0.1</td></tr><tr valign="top"><td align="left">Tek</td><td align="left">5.0</td><td align="left">2.2</td></tr><tr valign="top"><td align="left">Met</td><td align="left">>10.0</td><td align="left">>10.0</td></tr><tr valign="top"><td colspan="3" align="left">Cytoplasmic Tyrosine Kinase</td></tr><tr valign="top"><td align="left">Lck</td><td align="left">0.3</td><td align="left"><0.1</td></tr><tr valign="top"><td align="left">Abl1</td><td align="left">0.5</td><td align="left"><0.1</td></tr><tr valign="top"><td align="left">Src</td><td align="left">0.8</td><td align="left"><0.1</td></tr><tr valign="top"><td colspan="3" align="left">Serine/Threonine Kinase</td></tr><tr valign="top"><td align="left">Akt1</td><td align="left">>10.0</td><td align="left">>10.0</td></tr><tr valign="top"><td align="left">AuroraB</td><td align="left">>10.0</td><td align="left">>10.0</td></tr><tr valign="top"><td align="left">CDK2</td><td align="left">>10.0</td><td align="left">>10.0</td></tr><tr valign="top"><td align="left">MAPK1</td><td align="left">>10.0</td><td align="left">>10.0</td></tr><tr valign="top"><td align="left">Raf1</td><td align="left">10.0</td><td align="left">10.0</td></tr><tr valign="top"><td align="left">PKCα</td><td align="left">>10.0</td><td align="left">>10.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">This test was conducted by Invitrogen Select Screen Biochemical Kinase (SSBK) Profiling Service.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">The IC<sub>50</sub> was calculated from data at three different concentrations: 0.1, 1, and 10 μM.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetic Studies and In Vivo Efficacy of <b>19c</b> and <b>19d</b></h3><div class="NLM_p">Prior to clinical studies, our leading novel compounds <b>19c</b> and <b>19d</b> were subjected to pharmacokinetic studies in male rats. For an in vivo study, <b>19c</b> and <b>19d</b> were prepared as hydrochloride salt and mesylate, respectively. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, pharmacokinetic parameters for <b>19c</b> and <b>19d</b> were determined after a single oral administration (10 mg/kg) and intravenous injection (5 mg/kg). The selected compounds demonstrated fair oral bioavailability (<b>19c</b>, 76.5% and <b>19d</b>, 24.8%) and desirable exposure levels (<i>C</i><sub>max</sub> and AUC) in the rats. To evaluate their anticancer efficacy in vivo, <b>19c</b> and <b>19d</b> were dosed in female nude mice xenografted with Her-1-positive A431 cell lines. The in vivo efficacies of compounds <b>19c</b> and <b>19d</b> were compared to <b>3</b> (Lapatinib) as a positive control; the dose of each agent (3 mg/kg for <b>19c</b>−<b>d</b> and 10 mg/kg for <b>3</b>) was selected based on their in vitro enzymatic and cellular activities such that a comparable efficacy was obtained in all treatment groups. After once-daily oral dosing for 11 days, compounds <b>19c</b> and <b>19d</b> produced a significant reduction in tumor size (inhibition rate<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> on day 11: 66% for <b>19c</b>, 74% for <b>19d</b>). In comparison, <b>3</b> (Lapatinib) had a marginal effect on tumor reduction (4.5%) even at a 10 mg/kg dosage. Change in body weight was also monitored during the in vivo efficacy experiment. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, significant body-weight loss was not observed during treatment with <b>19c</b> and <b>19d</b>, consistent with treatment with <b>3</b> (Lapatinib) or no treatment. To examine the tolerability of our leading agent <b>19c</b>, we conducted secondary in vivo experiment with oral administration of <b>19c</b> at raised doses for 11 days in A431-xenografted nude mice. Even at high doses of <b>19c</b> (12.5, 25, and 50 mg/kg), the body-weight change was within 5% (compared to their initial body-weight), which confirms that our novel therapeutic agent <b>19c</b> has high safety margin in in vivo systems (see Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Profiles of Selected Compounds in Male Rats</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top"><th align="center">parameters (po)</th><th align="center"><b>19c</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th align="center"><b>19d</b><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top"><td align="left">AUC<sub>last</sub> (ng·h/mL)</td><td align="left">2019.3 ± 205.2</td><td align="left">428.50 ± 27.91</td></tr><tr valign="top"><td align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td align="left">1745.7 ± 170.2</td><td align="left">146.86 ± 17.42</td></tr><tr valign="top"><td align="left"><i>T</i><sub>1/2</sub> (h)</td><td align="left">3.2 ± 0.7</td><td align="left">4.2 ± 1.1</td></tr><tr valign="top"><td align="left"><i>F</i> (%)</td><td align="left">76.5</td><td align="left">24.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last"><b>19c</b> was treated as HCl salt.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last"><b>19d</b> was treated as mesylate.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">The used vehicle was 20% PEG400 in distilled water and the pharmacokinetic parameters were determined after a single oral administration (10 mg/kg, <i>n</i> = 5) and intravenous injection (5 mg/kg, <i>n</i> = 3).</p></div></div></div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antitumor activity during treatment with <b>19c</b> (as HCl salt), <b>19d</b> (as mesylate), <b>3</b> (Lapatinib), or vehicle control in an A431-xenograft model in nude mice. Each compound was administered through once-daily oral treatments for 11 days from the 7th day after implantation. The used vehicle was 20% PEG400 in distilled water. Compounds <b>19c</b> (as HCl salt), <b>19d</b> (as mesylate), and <b>3</b> (Lapatinib) were administered at 3, 3, and 10 mg/kg, respectively. Initial group size was eight animals for all groups. All biological data were obtained from a single experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Body weight change during treatment with <b>19c</b> (as HCl salt), <b>19d</b> (as mesylate), <b>3</b> (Lapatinib), or the vehicle control in an A431-xenograft model in nude mice. See Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> for detailed study conditions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Body weight change during treatment with <b>19c</b> (as HCl salt) at higher doses (12.5, 25, and 50 mg/kg) or the vehicle control in an A431-xenograft model in nude mice. See Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> for details of study conditions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15748" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15748" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Herein, we have described the synthesis of a novel series of (<i>S</i>)-1-acryloyl-<i>N</i>-[4-(arylamino)-7-(alkoxy)quinazolin-6-yl]pyrrolidine-2-carboxamides, which are potent Her-1/Her-2 dual inhibitors for the treatment of <b>1</b> (Gefitinib)/<b>2</b> (Erlotinib)-resistant non-small cell lung cancer. In contrast to the Her-1 selective inhibitors, <b>1</b> and <b>2</b>, our novel compounds are irreversible inhibitors of Her-1 and Her-2 tyrosine kinases with the potential to overcome clinically relevant, mutation-induced drug (<b>1</b> and <b>2</b>) resistance.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> SAR studies of these series identified that the preferred orientation and special location of Cys-capturing acrylamide moiety from the key binding motif, 6-aminoquinazoline. Based on our systematic structural modification on the linker region, conformationally rigid <span class="smallcaps smallerCapital">l</span>-proline at the C<sub>6</sub> position showed the strongest potency for Her-1/Her-2 dual inhibition activity. In addition, methoxyethyloxy functionality at the C<sub>7</sub> position of the quinazoline and di- or trihalogen-substituted anilines at the C<sub>4</sub> position were essential for enhanced efficacy in in vitro enzymatic as well as in vitro cellular assays. The selected compounds (<b>19c</b> and <b>19d</b>) showed excellent EGFR inhibition activity even toward the <b>1</b> (Gefitinib)- and <b>2</b> (Erlotinib)-resistant T790M mutation of Her-1 tyrosine kinase. The leading compound <b>19c</b> also showed excellent selectivity in an enzyme-based inhibition assay with a panel of 25 kinases. We confirmed that our leading Her-1/Her-2 dual inhibitor (<b>19c</b>) has an irreversible binding mode<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> to EGFR through a cell washout test, without cellular toxicity toward a normal cell line (Hs27). The excellent pharmacokinetic profiles of these compounds in rats and their robust in vivo efficacy in an A431-xenograft model clearly demonstrated that they merit further investigation as novel therapeutic agents for EGFR-targeting treatment of solid tumors, especially <b>1</b> (Gefitinib)/<b>2</b> (Erlotinib)-resistant non-small cell lung cancer.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12060" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12060" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> General Information</h4><div class="NLM_p last">All commercial chemicals and solvents were reagent grade and were used without further purification unless otherwise specified. All reported yields are isolated yields after chromatography or crystallization. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker DRX-300 (Bruker Biospin, Germany) and Varian Inova-500 (Varian Assoc., Palo Alto, CA), Chemical shifts are reported in ppm relative to the residual solvent peak (CDCl<sub>3</sub>, <sup>13</sup>C 77.00; TMS: 0.00). Multiplicity was indicated as follows: s (singlet); d (doublet); t (triplet); q (quartet); m (multiplet); dd (doublet of doublet); ddd (doublet of doublet of doublet); dt (triplet of doublet); td (doublet of triplet); br s (broad singlet), and so on. The high resolution mass spectrometric analyses were conducted at the Mass Spectrometry Laboratory of Seoul National University using mass spectrometer by direct injection for fast atomic bombardment (FAB). Products were purified by flash column chromatography on silica gel (230−400 mesh). The eluent used for purification is reported in parentheses. High performance liquid chromatography analyses for checking purity (>95% area) of synthesized compounds were performed on SHIMADZU HPLC equipped with a reverse phase column (XDB C18, 5 μm, 4.6 × 150 mm). Samples were analyzed starting with 5% ACN in H<sub>2</sub>O (0.1% TFA) for 5 min after injected 10 μL of sample and solvent was changed from 5% ACN in H<sub>2</sub>O (0.1% TFA) to 100% ACN (0.1% TFA) for 45 min with 1.0 mL/min flow. Absorbance was detected by 254 nm. Thin-layer chromatography (TLC) was performed on precoated glass-backed plates (silica gel 60 F<sub>254</sub> 0.25 mm), and the components were visualized by observation under UV light (254 and 365 nm) or by treating the plates with anisaldehyde, KMnO<sub>4</sub>, and phosphomolybdic acid followed by heating. Distilled water was polished using ion exchange and filtration.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> General Procedures for the Synthesis of <b>13a</b>−<b>h</b></h4><div class="NLM_p last">To a stirred solution of <i>N</i><sup><i>4</i></sup>-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazoline-4,6-diamine<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (150 mg, 0.4 mmol) in pyridine (6 mL) were added the appropriate <i>N</i>-Boc-amino acid (1.0 mmol) and 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (300 mg, 1.5 mmol). After being stirred at room temperature for 2 h, the reaction mixture was distilled under reduced pressure to remove pyridine and diluted with water, the aqueous layer was extracted three times with a mixture of chloroform and isopropanol (3:1), and the organic extract was washed with water and brine and dried over anhydrous sodium sulfate. The solvent was evaporated and the crude mixture was dried under reduced vacuum. The resulting residue was dissolved in a mixture of methylene chloride (7 mL) and trifluoroacetic acid (3 mL) and stirred at room temperature for 1 h. The resulting reaction mixture was concentrated under reduced pressure and saturated sodium bicarbonate (aq) was added slowly to the resulting residue while stirring to make it weakly alkaline. The reaction mixture thus obtained was extracted with a mixture of chloroform and isopropanol (3:1). The combined organic extract was dried over anhydrous sodium sulfate and concentrated under a reduced pressure to obtain a crude product, which was purified by silica gel flash column chromatography (methanol/chloroform = 1:9). To a stirred solution of acrylic acid (15 μL, 0.22 mmol) in THF (2 mL) at 0 °C were added 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide hydrochloride (48 mg, 0.25 mmol), pyridine (20 μL, 0.25 mmol), and the purified compound (100 mg, 0.21 mmol). After being stirred at 0 °C for 1 h, the reaction mixture was diluted with sodium bicarbonate aqueous solution, the aqueous layer was extracted three times with chloroform, and the organic extract was washed with water and brine and dried over anhydrous sodium sulfate. The solvent was evaporated and the crude mixture was purified by silica gel flash column chromatography (methanol/ethyl acetate/methylene chloride = 1:7:7) to obtain a desired product.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl]azetidine-2-carboxamide (<b>13a</b>)</h4><div class="NLM_p last">Pale yellow solid, 89% yield. <sup>1</sup>H NMR (CDC1<sub>3</sub>, 300 MHz): δ 9.95 (s, 1H), 8.82 (d, 1H), 8.69 (s, 1H), 8.59 (d, 1H), 7.91(d, 1H), 7.88 (d, 1H), 7.73 (td, 1H), 7.66 (m, 1H), 7.54 (td, 2H), 7.24 (m, 1H), 7.02 (d, 1H), 5.30 (s, 2H), 4.51 (t, 1H), 3.90 (q, 1H), 3.42 (m, 1H), 2.77 (m, 1H), 2.50 (m, 1H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 1-Acryloyl-<i>N</i>-[4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl]azetidine-3-carboxamide (<b>13b</b>)</h4><div class="NLM_p last">Pale yellow solid, 55% yield. <sup>1</sup>H NMR (CDC1<sub>3</sub>, 300 MHz): δ 8.85 (s, 1H), 8.79 (s, 1H), 8.70 (s, 1H), 8.60 (d, 1H), 7.89 (d, 1H), 7.86 (d, 1H), 7.76 (t, 1H), 7.66 (d, 1H), 7.51 (m, 2H), 7.03 (d, 1H), 5.31 (s, 2H), 4.01 (t, 2H), 3.85 (t, 2H), 3.40 (m, 1H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (<i>S</i>)<i>-</i>1-Acryloyl-<i>N</i>-[4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl]pyrrolidine-2-carboxamide (<b>13c</b>)</h4><div class="NLM_p last">Pale yellow solid, 57% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.22 (s, 1H), 9.65 (s, 1H), 8.54 (d, 1H), 8.45 (s, 1H), 8.17 (d, 1H), 7.95 (s, 1H), 7.82 (t, 1H), 7.67 (m, 2H), 7.52 (d, 1H), 7.30 (t, 1H), 7.20 (d, 1H), 5.23 (s, 2H), 3.75 (m, 1H), 2.88 (m, 2H), 2.01 (m, 1H), 1.80 (m, 1H), 1.64 (m, 2H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (<i>S</i>)<i>-</i>1-Acryloyl-<i>N</i>-[4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl]pyrrolidine-3-carboxamide (<b>13d</b>)</h4><div class="NLM_p last">Pale yellow solid, 55% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 8.59 (m, 3H), 7.76−7.61 (m, 5H), 7.45 (d, 1H), 7.23 (t, 1H), 6.93 (d, 1H), 6.32 (m, 2H), 5.68 (m, 1H), 5.24 (s, 2H), 4.88 (bs, 1H), 3.80 (m, 2H), 3.58 (m, 1H), 3.15 (m, 1H), 2.40 (m, 1H), 2.20 (m, 1H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (<i>S</i>)<i>-</i>1-Acryloyl-<i>N</i>-[4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl]piperidine-2-carboxamide (<b>13e</b>)</h4><div class="NLM_p last">Pale yellow solid, 57% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 9.27 (s, 1H), 8.65 (s, 1H), 8.60 (d, 1H), 8.45 (s, 1H), 7.90 (d, 1H), 7.76 (t, 2H), 7.67 (d, 1H), 7.54 (m, 3H), 7.30 (d, 1H), 6.65 (dd, 1H), 6.44 (dd, 1H), 5.85 (dd, 1H), 4.00 (d, 1H), 3.25 (t, 1H), 2.30 (d, 1H), 2.03−1.58 (m, 6H).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>S</i>)<i>-</i>1-Acryloyl-<i>N</i>-[4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl]piperidine-3-carboxamide (<b>13f</b>)</h4><div class="NLM_p last">Pale yellow solid, 43% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 9.63 (s, 1H), 8.76 (s, 1H), 8.68 (s, 1H), 8.60 (d, 1H), 7.84 (m, 2H), 7.76 (m, 2H), 7.66 (d, 1H), 7.55 (m, 2H), 7.02 (d, 1H), 6.59 (dd, 1H), 6.39 (d, 1H), 5.81 (d, 1H), 5.30 (s, 2H), 4.43 (d, 1H), 3.77 (m, 1H), 3.64 (m, 1H), 3.49 (m, 1H), 2.80 (m, 1H), 2.48 (m, 1H), 1.70 (m, 3H).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 1-Acryloyl-<i>N</i>-[4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl]piperidine-4-carboxamide (<b>13g</b>)</h4><div class="NLM_p last">Pale yellow solid, 11% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 8.76 (s, 1H), 8.69 (s, 1H), 8.60 (d, 1H), 7.85 (m, 2H), 7.75 (m, 1H), 7.66 (m, 1H), 7.50 (m, 2H), 7.42 (d, 1H), 7.01 (d, 1H), 6.58 (dd, 1H), 6.30 (dd, 1H), 5.73 (dd, 1H), 5.29 (s, 2H), 4.70 (bs, 1H), 3.20 (m, 1H), 2.80 (m, 2H), 2.50 (m, 1H), 1.82 (m, 4H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>R</i>)<i>-</i>1-Acryloyl-<i>N</i>-[4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl]pyrrolidine-2-carboxamide (<b>13h</b>)</h4><div class="NLM_p last">Pale yellow solid, 68% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.22 (s, 1H), 9.65 (s, 1H), 8.54 (d, 1H), 8.45 (s, 1H), 8.17 (d, 1H), 7.95 (s, 1H), 7.82 (t, 1H), 7.67 (m, 2H), 7.52 (d, 1H), 7.30 (t, 1H), 7.20 (d, 1H), 5.23 (s, 2H), 3.75 (m, 1H), 2.88 (m, 2H), 2.01 (m, 1H), 1.80 (m, 1H), 1.64 (m, 2H).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Procedures for the Synthesis of <b>18a</b>−<b>d</b> and <b>19a</b>−<b>f</b></h4><div class="NLM_p last">The synthesis of <b>18a</b>−<b>d</b> and <b>19a</b>−<b>f</b> was performed using similar protocols for the synthesis of <b>13a</b>−<b>h</b> except using appropriate anilines<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and <i>N</i>-(<i>t</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-proline instead of <i>N</i><sup>4</sup>-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)quinazoline-4,6-diamine<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and the appropriate <i>N</i>-Boc-amino acid.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-methoxyquinazolin-6-yl]pyrrolidine-2-carboxamide (<b>18a</b>)</h4><div class="NLM_p last">Pale yellow solid, 25% yield. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 300 MHz): δ 8.76 (s, 1H), 8.55 (d, 1H), 8.40 (s, 1H), 7.88 (m, 2H), 7.71 (d, 1H), 7.55 (dd, 1H), 7.33 (t, 1H), 7.12 (m, 2H), 6.71 (dd, 1H), 6.36 (d, 1H), 5.82 (d, 1H), 5.23 (s, 2H), 4.85 (m, 1H), 4.02 (s, 3H), 3.81 (m, 2H), 2.03−2.27 (m, 4H).</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl]pyrrolidine-2-carboxamide (<b>18b</b>)</h4><div class="NLM_p last">White solid, 42% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.65 (s, 1H), 8.76 (s, 1H), 8.57 (s, 1H), 8.28 (s, 1H), 7.85 (dd, 1H), 7.57 (m, 1H), 7.08 (t, 1H), 6.98 (s, 1H), 6.55 (dd, 1H), 6.42 (dd, 1H), 5.78 (dd, 1 H), 4.95 (d, 1H), 3.76 (s, 3H), 3.76 (m, 1H), 3.65 (m, 1H), 2.50 (m, 1H), 2.10 (m, 3H).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl]pyrrolidine-2-carboxamide (<b>18c</b>)</h4><div class="NLM_p last">White solid, 28% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.83 (s, 1H), 9.52 (s, 1H), 8.81 (s, 1H), 8.06 (m, 1H), 7.73 (m, 1H), 7.38 (m, 1H), 7.27 (s, 1H), 6.67 (m, 1H), 6.20 (m, 1H), 5.74 (m, 1H), 4.73 (m, 1H), 4.30 (m, 2H), 3.63 (m, 2H), 3.61 (m, 2H), 3.32 (s, 3H), 2.09 (m, 2H), 1.95 (m, 2H).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-(2-methoxyethoxy) quinazolin-6-yl]pyrrolidine-2-carboxamide (<b>19a</b>)</h4><div class="NLM_p last">Pale yellow solid, 60% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.61 (s, 1H), 9.71 (s, 1H), 9.05 (s, 1H), 8.59 (d, 1H), 8.45 (s, 1H), 8.31 (s, 1H), 7.93 (d, 1H), 7.88 (td, 1H), 7.64 (dd, 1H), 7.58 (d, 1H), 7.37 (m, 2H), 7.28 (s, 2H), 7.23 (d, 1H), 5.28 (s, 2H), 4.36 (t, 2H), 3.82 (m, 1H), 3.79 (t, 2H), 3.40 (s, 3H), 2.68 (m, 2H), 2.10 (m, 2H), 1.67 (m, 2H).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(3-chloro-4-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl]pyrrolidine-2-carboxamide (<b>19b</b>)</h4><div class="NLM_p last">White solid, 28% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.83 (s, 1H), 9.52 (s, 1H), 8.81 (s, 1H), 8.06 (m, 1H), 7.73 (m, 1H), 7.38 (m, 1H), 7.27 (s, 1H), 6.67 (m, 1H), 6.20 (m, 1H), 5.74 (m, 1H), 4.73 (m, 1H), 4.30 (m, 2H), 3.63 (m, 2H), 3.61 (m, 2H), 3.32 (s, 3H), 2.09 (m, 2H), 1.95 (m, 2H).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(3-chloro-2-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl]pyrrolidine-2-carboxamide (<b>19c</b>)</h4><div class="NLM_p last">White solid, 10% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 9.99 (s, 1H), 9.07 (s, 1H), 8.68 (s, 1H), 8.39 (dd, 1H), 7.53 (s, 1H), 7.14 (d, 2H), 6.55 (d, 1H), 6.53 (s, 1H), 5.82 (dd, 1H), 4.94 (d, 1H), 4.34 (m, 2H), 3.96 (m, 2H), 3.77 (td, 1H), 3.62 (m, 1H), 3.50 (s, 3H), 2.64 (m, 1H), 2.14 (m, 2H), 1.95 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 169.8, 166.1, 156.4, 154.0, 152.7, 148.3, 129.2, 129.1, 127.9, 124.8, 124.4, 122.3, 121.8, 121.0, 109.6, 109.0, 107.5, 70.4, 68.4, 60.9, 59.1, 47.5, 26.9, 25.1; HRMS (FAB<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>25</sub>ClFN<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 514.1657. Found: 514.1658.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(3-chloro-2,4-difluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl]pyrrolidine-2-carboxamide (<b>19d</b>)</h4><div class="NLM_p last">White solid, 14% yield. <sup>1</sup>H NMR (CDC1<sub>3</sub>, 300 MHz): δ 9.95 (s, 1H), 9.03 (s, 1H), 8.60 (s, 1H), 8.06 (m, 1H), 7.62 (bs, 1H), 7.21 (s, 1H), 7.01 (m, 1H), 6.53 (m, 2H), 5.82 (m, 1H), 4.94 (m, 1H), 4.30 (m, 2H), 3.94 (m, 2H), 3.76 (m, 1H), 3.62 (m, 1H), 3.49 (s, 3H), 2.58 (m, 1H), 2.33 (m, 1H), 2.13 (m, 2H), 1.95 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub> + CD<sub>3</sub>OD, 1 drop): δ 170.1, 170.0, 166.0, 157.3, 154.2, 152.7, 152.6, 148.1, 129.3, 128.3, 127.8, 123.8, 123.7, 111.2, 111.1, 110.0, 109.3, 107.1, 70.3, 68.2, 60.9, 59.0, 47.5, 27.4, 25.0; HRMS (FAB<sup>+</sup>) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>24</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 532.1563. Found: 532.1575.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(3,4-dichloro-2-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl]pyrrolidine-2-carboxamide (<b>19e</b>)</h4><div class="NLM_p last">White solid, 10% yield. <sup>1</sup>H NMR (CDC1<sub>3</sub>, 300 MHz): δ 10.03 (s, 1H), 9.06 (s, 1H), 8.67 (s, 1H), 8.36 (t, 1H), 7.52 (s, 1H), 7.30 (dd, 1H), 7.24 (s, 1H), 6.55 (m, 2H), 5.83 (m, 1H), 4.95 (m, 1H), 4.33 (m, 2H), 3.95 (m, 2H), 3.76 (m, 1H), 3.62 (m, 1H), 3.51 (s, 3H), 2.61 (m, 1H), 2.13 (m, 2H), 1.97 (m, 1H).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(4-bromo-3-chloro-2-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl]pyrrolidine-2-carboxamide (<b>19f</b>)</h4><div class="NLM_p last">Ivory solid, 31% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 9.99 (s, 1H), 9.05 (s, 1H), 8.65 (s, 1H), 8.20 (t, 1H), 7.70 (bs, 1H), 7.43 (dd, 1H), 7.25 (s, 1H), 6.55 (m, 2H), 5.83 (m, 1H), 4.94 (m, 1H), 4.32 (m, 2H), 3.94 (m, 2H), 3.78 (m, 1H), 3.60 (m, 1H), 3.5 (s, 3H), 2.61 (m,1H), 2.10 (m, 3H).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(3-chloro-2-fluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl]pyrrolidine-2-carboxamide Hydrochloride (<b>19c</b> HCl)</h4><div class="NLM_p last">To a stirred solution of <b>19c</b> (1.0 g, 1.95 mmol) in isopropanol (20 mL) was slowly added 1 N HCl ethereal solution (4.88 mL, 4.88 mmol). After being stirred at room temperature for 1 h, the regenerated solid was collected through simple filtration with quick wash by cooled isopropanol and dried under reduced pressure. White solid, 94% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 10.38 (s, 1H), 9.22 (s, 1H), 8.80 (s, 1H), 8.66 (s, 1H), 8.04 (s, 1H), 7.90 (t, 1H), 7.39 (t, 1H), 7.25 (td, 1H), 6.54 (d, 2H), 5.85 (t, 1H), 4.95 (d, 1H), 4.45 (m, 2H), 3.95 (m, 2H), 3.70 (m, 1H), 3.50 (m, 1H), 3.48 (s, 3H), 2.50 (m, 1H), 2.14 (m, 2H), 2.00 (m, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 170.4, 166.0, 159.3, 155.0, 153.5, 151.5, 148.4, 136.8, 130.3, 129.5, 129.3, 127.9, 126.0, 124.6, 121.9, 111.6, 106.9, 100.2, 70.0, 69.6, 61.0, 59.1, 47.9, 27.4, 25.2.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>S</i>)-1-Acryloyl-<i>N</i>-[4-(3-chloro-2,4-difluorophenylamino)-7-(2-methoxyethoxy)quinazolin-6-yl]pyrrolidine-2-carboxamide Mesylate (<b>19d</b> Mesylate)</h4><div class="NLM_p last">To a stirred solution of <b>19d</b> (1.0 g, 1.88 mmol) in ethyl acetate (20 mL) was slowly added methanesulfonic acid (0.27 mL, 4.14 mmol). After being stirred at room temperature for 2 h, the regenerated solid was collected through simple filtration with quick wash by cooled ethyl acetate and dried under reduced pressure. Ivory solid, 86% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 9.85 (s, 1Η), 9.09 (s, 1H), 8.53 (s, 1H), 7.61 (m, 1H), 7.56 (s, 1H), 7.07 (m, 1H), 6.53 (dd, 1H), 6.44 (d, 1H), 5.85 (dd, 1H), 4.89 (t, 1H), 4.34 (m, 1H), 4.23 (m, 1H), 3.90 (m, 1H), 3.79 (m, 2H), 3.65 (m, 1H), 3.42 (s, 3H), 2.91 (s, 6H), 2.41 (m, 1H), 2.11 (m, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 170.2, 166.4, 159.5, 155.7, 154.6, 148.8, 136.8, 130.4, 130.1, 127.4, 125.8, 112.6, 111.8, 111.7, 110.9, 106.7, 100.3, 70.0, 69.8, 61.2, 58.9, 47.9, 39.3, 27.8, 24.9.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> General Procedures for the EGFR Enzyme Assay</h4><div class="NLM_p last">A total of 10 μL of EGFR enzyme (Her-1, Her-2, or Her-1 T790 M kinase, Upstate) was added to each well of a 96-well microplate. As an EGFR inhibitor, 10 μL of serially diluted solution of the synthesized compounds was added to the individual wells, and the plate was incubated at room temperature for 10 min. A total of 10 μL of Poly (Glu, Tyr 4:1, Sigma) and 10 μL of ATP were successively added to initiate a kinase reaction, and the resulting mixture was incubated at room temperature for 1 h. A total of 10 μL of 100 mM EDTA was added to each well and stirred for 5 min to terminate the kinase reaction. Then 10 μL of 10× antiphosphotyrosine antibody (Pan Vera), 10 μL of 10× protein tyrosine kinase (PTK) green tracer (Pan Vera), and 30 μL of fluorescence polarization (FP)-diluted buffer were added to the reacted mixture, followed by incubation in the dark at room temperature for 30 min. The FP value of each well was determined using a VICTORIII fluorescence meter (Perkin-Elmer) at 488 nm. The IC<sub>50</sub>, that is, the concentration at which 50% inhibition was observed, was determined by setting the maximum value (0% inhibition) to the polarized light value for a well untreated with EGFR inhibitor and the minimum value (100% inhibition). IC<sub>50</sub> calculations and analysis were carried out using Microsoft Excel.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> General Procedures for the Cell Growth Inhibitory Assay</h4><div class="NLM_p">A human vaginal epidermoid cancer cell line, A431 (ATCC: CRL-1555), a human breast cancer cell line, SK-Br3 (ATCC: HTB-30), and a primary human fibroblast cell-line, Hs27 (ATCC: CCL-34), were used to measure the inhibitory activities of the synthesized compounds toward cancer cell growth and cytotoxicity to normal cells. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/L glucose and 1.5 g/L sodium bicarbonate, and were supplemented with 10% fetal bovine serum (FBS). In addition, an Gefitinib/Erlotinib-resistant non-small cell lung cancer cell line, H1975 (ATCC: CRL-5908), was incubated in an RPMI medium containing 1% sodium pyruvate and 10% FBS. These cell lines, stored in a liquid nitrogen tank, were quickly thawed at 37 °C and centrifuged to remove the medium. The resulting cell pellet was mixed with the culture medium and incubated in a culture flask at 37 °C under 5% CO<sub>2</sub> for 2−3 days; thereafter, the medium was removed. The remaining cells were washed with Dulbecco’s phosphate buffered saline (DPBS) and were separated from the flask using Trypsin-EDTA. The separated cells were diluted with the culture medium to a concentration of 100000 cells/mL for A431 or Hs27 or 200000 cells/mL for SK-Br3. A total of 100 μL of the diluted cell solution was added to each well of a 96-well plate and incubated at 37 °C under 5% CO<sub>2</sub> for 1 day.</div><div class="NLM_p last">The synthesized compounds were dissolved in 99.5% DMSO to a concentration of 25 mM. If the test compound was not soluble in DMSO, a small amount of 1% HCl was added and the mixture was held in a 40 °C water bath for 30 min until complete dissolution was achieved. The test compound solution was diluted with culture medium to a final concentration of 100 μM and then diluted 10 times serially to 10<sup>−6</sup> μM (the final concentration of DMSO was less than 1%). The medium was then removed from each of 96 wells of the microplate. A total of 100 μL of the test compound solution was added to each well holding the cultured cells, and the microplate was incubated at 37 °C under 5% CO<sub>2</sub> for 72 h. After removing the medium from the plate, 50 μL 10% trichloroacetic acid was added to each well, and the plate was maintained at 37 °C for 1 h to fix the cells to the bottom of the plate. Trichloroacetic acid was removed from each well, the plate was dried, 100 μL of SRB dye solution was added, and the resulting mixture was reacted for 10 min. The SRB dye solution was prepared by dissolving SRB in 1% acetic acid to a concentration of 0.4% by wt. After removing the dye solution, the plate was washed with water and dried. If the dye solution was not effectively removed by washing with water, 1% acetic acid was used. Trizma base (10 mM) in the amount of 150 μL was added to each well, and absorbance at 570 nm was determined using a microplate reader. For H1975, the cells were diluted with the culture medium to a concentration of 50000 cells/mL. Diluted cell solution (100 μL) was added to each well of a 96-well microplate, and after 1 day of incubation at 37 °C under 5% CO<sub>2</sub>, each well was washed with a mixture of RPMI, 0.1% FBS, and 1% penicillin-streptomycin (PS), followed by replacement of the medium. The plate was held overnight and treated with various concentrations under the same medium conditions for 48 h. Similar to an MTT assay, 15 μL of a CellTiter oneshot solution (Promega) was added to each well and incubated for 2−3 h, and the absorbance at 490 nm was determined. The IC<sub>50</sub> value was calculated based on the difference between the final concentration of test cells and the initial concentration of the cells incubated in a well untreated with the test compound which was considered 100%. IC<sub>50</sub> calculations were carried out using Microsoft Excel.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Pharmacokinetic Studies</h4><div class="NLM_p last">Male rats (Sprague−Dawley rats, body-weight range: 250 ± 10 g, i.v.: <i>n</i> = 3, p.o.: <i>n</i> = 5) were administered the test compounds intravenously via the tail vein at 5 mg/kg or orally at 10 mg/kg by gavage in a solution of 20% PEG400 in distilled water. For the in vivo study, <b>19c</b> and <b>19d</b> were prepared as HCl salt and mesylate, respectively. At predetermined times 24 h or more after dosing, 0.3 mL of blood was collected from the jugular vein using a tube containing anticoagulant (1000 IU/mL, heparin, 3 μL). The plasma was separated by centrifugation (12000 rpm, 2 min, Eppendorf). The concentrations of the compounds were measured in the plasma using LC/MS/MS after protein precipitation with acetonitrile. The relevant estimated pharmacokinetic parameters for plasma were derived using WinNonlin Version 5.2 (Pharsight).</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> In Vivo Efficacy Study</h4><div class="NLM_p last">A total of 30 mg of mouse A431 tumor fragments was implanted subcutaneously into the right flank of NU/NU Balb/C mice (female, body-weight range: 20 ± 5 g). Treatment was initiated approximately 7 days after implantation. Animals were randomized into treatment groups (<i>n</i> = 8) with similar mean tumor volumes in milligrams<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> of 187.4 mg. For the in vivo study, <b>19c</b> and <b>19d</b> were prepared as HCl salt and mesylate, respectively, and the vehicle was 20% PEG400 in distilled water. Doses (10 mg/kg for <b>3</b>, 3 mg/kg for <b>19c</b> and <b>19d</b>) were body-weight-adjusted at the time of dosing. Compounds <b>3</b>, <b>19c</b>, and <b>19d</b> as test compounds and the vehicle as a control were orally administered once daily for 11 days. Tumor volumes (mg) and body weights (g) were recorded twice a week from all groups using a Vernier caliper and balance.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44"><a href="/doi/suppl/10.1021/jm901146p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02883" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02883" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H NMR, <sup>13</sup>C NMR, and in vivo efficacy data for our leading compounds (<b>19c</b> and <b>19d</b>). This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm901146p/suppl_file/jm901146p_si_001.pdf">jm901146p_si_001.pdf (263.69 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm901146p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86008" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86008" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Seung Bum Park</span> - <span class="hlFld-Affiliation affiliation">Department of Biophysics and Chemical Biology, Seoul National University, Seoul 151-747, Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fb90929688bb939a959692d59894d59089db88998b9a8990bb88958ed59a98d59089"><span class="__cf_email__" data-cfemail="7b101216083b131a151612551814551009">[email protected]</span> <span class="__cf_email__" data-cfemail="87f4e5f7e6f5ecc7f4e9f2a9e6e4a9ecf5">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maeng Sup Kim</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon, Hwaseong, Gyeonggi-do, 445-813, Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a5ceccc8d6e5cdc4cbc8cc8bc6ca8bced785d6c7d5c4d7cee5d6cbd08bc4c68bced7"><span class="__cf_email__" data-cfemail="acc7c5c1dfecc4cdc2c1c582cfc382c7de">[email protected]</span> <span class="__cf_email__" data-cfemail="a5d6c7d5c4d7cee5d6cbd08bc4c68bced7">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mi Young Cha</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon, Hwaseong, Gyeonggi-do, 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kwang-Ok Lee</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon, Hwaseong, Gyeonggi-do, 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jong Woo Kim</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon, Hwaseong, Gyeonggi-do, 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chang Gon Lee</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon, Hwaseong, Gyeonggi-do, 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ji Yeon Song</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon, Hwaseong, Gyeonggi-do, 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Young Hoon Kim</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon, Hwaseong, Gyeonggi-do, 445-813, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gwan Sun Lee</span> - <span class="hlFld-Affiliation affiliation">Department of Drug Discovery, Hanmi Research Center, 377-1 Yeongcheon-ri, Dongtan-myeon, Hwaseong, Gyeonggi-do, 445-813, Korea</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="ack"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88801" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88801" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was supported by the Korea Ministry of Knowledge Economy (Grant No. 10016636), the Korea Science and Engineering Foundation (KOSEF), and the WCU program through KOSEF funded by the Korean Ministry of Education, Science, and Technology (MEST).</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48160" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48160" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 26 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0lj9Pz_2LcD4pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ERBB receptors and cancer: the complexity of targeted inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lj9Pz_2LcD4pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB signaling network</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+signaling+network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0lj9Pz_2LcD4pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signaling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, C. J.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1053%2Fsonc.2002.31525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11894011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVKjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2002&pages=27-36&author=R.+S.+Herbstauthor=C.+J.+Langer&title=Epidermal+growth+factor+receptors+as+a+target+for+cancer+treatment%3A+The+emerging+role+of+IMC-C225+in+the+treatment+of+lung+and+head+and+neck+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers</span></div><div class="casAuthors">Herbst, Roy S.; Langer, Corey J.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1, Suppl. 4</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor is 1 of 4 receptors crit. to cellular proliferation, differentiation, and survival, and is widely expressed in malignant tissue, particularly in squamous cell carcinoma of the head and neck.  Expression has been assocd. with malignant progression, inhibition of apoptosis, neoplastic angiogenesis, enhanced metastatic potential, and both chemoresistance and radioresistance.  IMC-C225 is a chimeric monoclonal antibody that targets extracellular epidermal growth factor receptor; it has shown both in vitro and in vivo antitumor activity in tumor cell lines expressing epidermal growth factor receptor, including heightened radiation response in vitro in cultured human squamous cell carcinoma and enhancement of Taxane- and platinum-induced cytotoxicity in non-small cell lung cancer xenografts.  In A431 head and neck squamous cell xenografts, IMC-C225 administered both before and after radiation therapy yields a radiation enhancement factor of 3.62, attributable to both tumor necrosis and antiangiogenesis.  In phase I pharmacokinetic studies, IMC-C225 has a long half-life, lending itself to convenient weekly administration.  It has shown a favorable toxicity profile, limited primarily to allergic and dermatol. reactions, the latter characterized by a self-limited, sterile, acneiform rash.  Anaphylaxis is rare.  Std. treatment entails a loading dose of 400 mg/m2 at week 1, followed by a maintenance dose of 250 mg/m2 weekly.  An ongoing phase III international multicenter, randomized study in locally advanced squamous cell carcinoma of the head and neck is evaluating therapeutic radiation therapy, either alone or in conjunction with IMC-C225.  In a pilot trial, 6 of 9 patients with platinum-exposed squamous cell carcinoma of the head and neck exhibited objective response.  In an ongoing phase II trial in patients with stable or progressive disease on platinum-based therapy, the preliminary response rate is ∼20%, far higher than one would expect with std. salvage regimens.  The Eastern Cooperative Oncol. Group has completed a placebo-controlled phase III registration trial assessing cisplatin 100 mg/m2 every 4 wk with or without IMC-C225.  Three sep. phase II trials in non-small cell lung cancer have been launched: one trial tests IMC-C225 in combination with std. Paclitaxel/carboplatin; another integrates IMC-C225 into the Gemcitabine/carboplatin combination in treatment-naive patients; and a third trial evaluates IMC-C225 in combination with Docetaxel 75 mg/m2 every 3 wk in the second-line setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-zUXfAK2Y_bVg90H21EOLACvtfcHk0liCFnA1_kP7eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVKjsr4%253D&md5=b7e524110b0af8a59ad341741a4fb48d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1053%2Fsonc.2002.31525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fsonc.2002.31525%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptors%2520as%2520a%2520target%2520for%2520cancer%2520treatment%253A%2520The%2520emerging%2520role%2520of%2520IMC-C225%2520in%2520the%2520treatment%2520of%2520lung%2520and%2520head%2520and%2520neck%2520cancers%26jtitle%3DSemin.%2520Oncol.%26date%3D2002%26volume%3D29%26spage%3D27%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: from rational design to clinical trials</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">499</span><span class="NLM_x">–</span> <span class="NLM_lpage">512</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1002%2Fmed.1022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11607931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotVeht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=499-512&author=P.+Traxlerauthor=G.+Boldauthor=E.+Buchdungerauthor=G.+Caravattiauthor=P.+Furetauthor=P.+Manleyauthor=T.+O%E2%80%99Reillyauthor=J.+Woodauthor=J.+Zimmermann&title=Tyrosine+kinase+inhibitors%3A+from+rational+design+to+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors: From rational design to clinical trials</span></div><div class="casAuthors">Traxler, Peter; Bold, Guido; Buchdunger, Elisabeth; Caravatti, Giorgio; Furet, Pascal; Manley, Paul; O'Reilly, Terence; Wood, Jeanette; Zimmermann, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">499-512</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Protein kinases play a crucial role in signal transduction as well as in cellular proliferation, differentiation, and various regulatory mechanisms.  The inhibition of growth related kinases, esp. Tyr kinases, might provide new therapies for diseases such as cancer.  The progress made in the crystn. of protein kinases has confirmed that the ATP-binding domain of Tyr kinases is an attractive target for drug design.  Three successful examples of drug design at Novartis using a Tyr kinase as a mol. target are described.  PK1166, a pyrrolo[2,3,-d]pyrimidine deriv., is a dual inhibitor of both the EGFR and the ErbB2 kinases.  The compd. entered clin. trials in 1999, based on its favorable pre-clin. profile: potent inhibition of EGF-mediated signalling in cells, in vivo antitumor activity in several EGFR over-expressing xenograft tumor models in nude mice, long-lasting inhibition of EGF-stimulated EGFR auto-phosphorylation in tumor tissue, good oral bioavailability in animals, and no prohibitive in vitro and in vivo toxicity findings.  The anilino-phthalazine deriv. PTK787/ZK222584 (Phase I, co-developed by Schering AG, Berlin) is a potent and selective inhibitor of both the KDR and Flt-1 kinases with interesting anti-angiogenic and pharmacokinetic properties (orally bioavailable).  STI 571 (Glivec, Gleevec), a phenylamino-pyrimidine deriv., is a potent inhibitor of the Abl Tyr kinase, which is present in 95% of patients with chronic myelogenous leukemia (CML).  The compd. specifically inhibits proliferation of v-Abl and Bcr-Abl expressing cells (including cells from CML patients) and shows anti-tumor activity as a single agent in animal models at well-tolerated doses.  Pharmacol. relevant concns. are achieved in the plasma of animals (oral administration).  Promising data from phase I and II clin. trials in CML patients (98% hematol. response rate in Phase I) support the fact that the STI571 represents a new treatment modality for CML.  In addn., potent inhibition of the PDGFR and c-Kit Tyr kinases also indicates its possible clin. use in solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4W1Gy1U-gvLVg90H21EOLACvtfcHk0liCFnA1_kP7eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotVeht7c%253D&md5=bc5ca99f96e51da0736842df4fea841e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fmed.1022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.1022%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DZimmermann%26aufirst%3DJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520from%2520rational%2520design%2520to%2520clinical%2520trials%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2001%26volume%3D21%26spage%3D499%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1087</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1358%2Fdof.2001.026.11.858717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVyltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2001&pages=1087-1092&author=A.+A.+Adjei&title=Epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy</span></div><div class="casAuthors">Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1087-1092</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are transmembrane proteins involved in signal transduction.  They propagate growth factor signals from the cell surface to intracellular processes that control crit. functions such as growth, differentiation, angiogenesis and inhibition of apoptosis.  In malignancies, these signaling pathways are often exploited to optimize tumor growth and metastasis.  One such family of receptor tyrosine kinases is the epidermal growth factor receptor (EGFR) tyrosine kinase.  These receptors are overexpressed in a wide variety of epithelial cancers and have been implicated in tumor aggressiveness.  Thus, targeting the EGFR tyrosine kinase has attracted considerable attention.  This review will summarize current preclin. and clin. knowledge of the small-mol. oral inhibitors of the EGFR tyrosine kinase, which include ZD-1839, OSI-774, CI-1033, EKB-569, PKI-166, GW-2016 and BIBX-1382.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfB_TYrS4ANrVg90H21EOLACvtfcHk0liCFnA1_kP7eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVyltg%253D%253D&md5=1c66b23e86d02cfaa5e719f5c0fcd53e</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1358%2Fdof.2001.026.11.858717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2001.026.11.858717%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DDrugs%2520Future%26date%3D2001%26volume%3D26%26spage%3D1087%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Renhowe, P. A.</span><span> </span><span class="NLM_article-title">Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy-clinical progress</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2002&pages=214-224&author=P.+A.+Renhowe&title=Inhibitors+of+growth+factor+receptor+kinase-dependent+signaling+pathways+in+anticancer+chemotherapy-clinical+progress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520growth%2520factor%2520receptor%2520kinase-dependent%2520signaling%2520pathways%2520in%2520anticancer%2520chemotherapy-clinical%2520progress%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2002%26volume%3D5%26spage%3D214%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tullo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Averbuch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyereislova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">–</span> <span class="NLM_lpage">2250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1200%2FJCO.2002.10.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11980995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVKrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=2240-2250&author=M.+Ransonauthor=L.+A.+Hammondauthor=D.+Ferryauthor=M.+Krisauthor=A.+Tulloauthor=P.+I.+Murrayauthor=V.+Millerauthor=S.+Averbuchauthor=J.+Ochsauthor=C.+Morrisauthor=A.+Feyereislovaauthor=H.+Swaislandauthor=E.+K.+Rowinsky&title=ZD1839%2C+a+selective+oral+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitor%2C+is+well+tolerated+and+active+in+patients+with+solid%2C+malignant+tumors%3A+results+of+a+phase+I+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial</span></div><div class="casAuthors">Ranson, Malcolm; Hammond, Lisa A.; Ferry, David; Kris, Mark; Tullo, Andrew; Murray, Philip I.; Miller, Vince; Averbuch, Steve; Ochs, Judy; Morris, Charles; Feyereislova, Andrea; Swaisland, Helen; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2240-2250</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.  Patients and Methods: This was an open, phase I, escalating multiple-dose tolerability and pharmacokinetic trial.  ZD1839 was administered once daily for 14 consecutive days followed by 14 days off treatment.  Dose escalation started at 50 mg/d and continued to 925 mg or until consistent dose-limiting toxicity (DLT) was obsd.  Results: Sixty-four patients were entered at eight dose levels.  The most frequent dose-related grade 1 and 2 adverse events were an acne-like (or folliculitis) rash, nausea, and diarrhea.  Three of nine patients treated at 700 mg/d developed DLT (reversible grade 3 diarrhea); grade 3 and 4 events were uncommon.  Exposure to ZD1839 was dose proportional, and the mean terminal half-life was 48 h (range, 37 to 65).  Four of 16 patients with non-small-cell lung cancer (NSCLC) had objective partial responses obsd. from ZD1839 300 to 700 mg/d.  Overall, 16 patients remained on study for ≥ 3 mo, with seven of these patients (five with NSCLC, including three of the patients with partial response) remaining on study for ≥ 6 mo.  Conclusion: ZD1839 was well tolerated, with DLT obsd. at a dose well above that at which antitumor activity was seen.  Pharmacokinetic anal. confirmed that ZD1839 was suitable for administration as a once-daily oral tablet formulation.  Phase II monotherapy and phase III combination trials in NSCLC are being conducted to investigate further the efficacy, tolerability, and optimal daily dose of ZD1839.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDgNViETgVS7Vg90H21EOLACvtfcHk0lh-ulSdXydQgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVKrsrc%253D&md5=b2de082b8b9292bb6cc62e4ea0a7b166</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.10.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.10.112%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DHammond%26aufirst%3DL.%2BA.%26aulast%3DFerry%26aufirst%3DD.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DTullo%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DP.%2BI.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DAverbuch%26aufirst%3DS.%26aulast%3DOchs%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DFeyereislova%26aufirst%3DA.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DZD1839%252C%2520a%2520selective%2520oral%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitor%252C%2520is%2520well%2520tolerated%2520and%2520active%2520in%2520patients%2520with%2520solid%252C%2520malignant%2520tumors%253A%2520results%2520of%2520a%2520phase%2520I%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D2240%26epage%3D2250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Ciardiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2958</span><span class="NLM_x">–</span> <span class="NLM_lpage">2970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11595683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvF2ktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=2958-2970&author=F.+Ciardielloauthor=G.+Tortora&title=A+novel+approach+in+the+treatment+of+cancer%3A+Targeting+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor</span></div><div class="casAuthors">Ciardiello, Fortunato; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2958-2970</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) autocrine pathway contributes to a no. of processes important to cancer development and progression, including cell proliferation, apoptosis, angiogenesis, and metastatic spread.  The crit. role the EGFR plays in cancer has led to an extensive search for selective inhibitors of the EGFR signaling pathway.  The results of a large body of preclin. studies and the early clin. trials thus far conducted suggest that targeting the EGFR could represent a significant contribution to cancer therapy.  A variety of different approaches are currently being used to target the EGFR.  The most promising strategies in clin. development include monoclonal antibodies to prevent ligand binding and small mol. inhibitors of the tyrosine kinase enzymic activity to inhibit autophosphorylation and downstream intracellular signaling.  At least five blocking monoclonal antibodies have been developed against the EGFR.  Among these, IMC-225 is a chimeric human-mouse monoclonal IgG1 antibody that has been the first anti-EGFR targeted therapy to enter clin. evaluation in cancer patients in Phase II and III studies, alone or in combination with conventional therapies, such as radiotherapy and chemotherapy.  A no. of small mol. inhibitors of the EGFR tyrosine kinase enzymic activity is also in development.  OSI-774 and ZD1839 (Iressa) are currently in Phase II and III development, resp.  ZD1839, a p.o. active, selective quinazoline deriv. has demonstrated promising in vitro and in vivo antitumor activity.  Preliminary results from Phase I and II trials in patients with advanced disease demonstrate that ZD1839 and OSI-774 have an acceptable tolerability profile and promising clin. efficacy in patients with a variety of tumor types.  This mini-review describes the EGFR inhibitors in clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWMqDAds0bV7Vg90H21EOLACvtfcHk0lh-ulSdXydQgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvF2ktbk%253D&md5=b83b93c1e98ab401ae809dac422fbb3c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DA%2520novel%2520approach%2520in%2520the%2520treatment%2520of%2520cancer%253A%2520Targeting%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D2958%26epage%3D2970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagrath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inserra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederichs, S.</span><span> </span><span class="NLM_article-title">Detection of mutations in EGFR in circulating lung-cancer cells</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">366</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1056%2FNEJMoa0800668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=18596266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFSqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=366-377&author=S.+Maheswaranauthor=L.+V.+Sequistauthor=S.+Nagrathauthor=L.+Ulkusauthor=B.+Branniganauthor=E.+Inserraauthor=S.+Diederichs&title=Detection+of+mutations+in+EGFR+in+circulating+lung-cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of mutations in EGFR in circulating lung-cancer</span></div><div class="casAuthors">Maheswaran, Shyamala; Sequist, Lecia V.; Nagrath, Sunitha; Ulkus, Lindsey; Brannigan, Brian; Collura, Chey V.; Inserra, Elizabeth; Diederichs, Sven; Iafrate, A. John; Bell, Daphne W.; Digumarthy, Subba; Muzikansky, Alona; Irimia, Daniel; Settleman, Jeffrey; Tompkins, Ronald G.; Lynch, Thomas J.; Toner, Mehmet; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">366-377</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The use of tyrosine kinase inhibitors to target the epidermal growth factor receptor gene (EGFR) in patients with non-small-cell lung cancer is effective but limited by the emergence of drug-resistance mutations.  Mol. characterization of circulating tumor cells may provide a strategy for noninvasive serial monitoring of tumor genotypes during treatment.  Methods: The authors captured highly purified circulating tumor cells from the blood of patients with non-small-cell lung cancer using a microfluidic device contg. microposts coated with antibodies against epithelial cells.  The authors performed EGFR mutational anal. on DNA recovered from circulating tumor cells using allele-specific polymerase-chain-reaction amplification and compared the results with those from concurrently isolated free plasma DNA and from the original tumor-biopsy specimens.  Results: The authors isolated circulating tumor cells from 27 patients with metastatic non-small-cell lung cancer (median no., 74 cells per mL).  The authors identified the expected EGFR activating mutation in circulating tumor cells from 11 of 12 patients (92%) and in matched free plasma DNA from 4 of 12 patients (33%) (P = 0.009).  The authors detected the T790M mutation, which confers drug resistance, in circulating tumor cells collected from patients with EGFR mutations who had received tyrosine kinase inhibitors.  When T790M was detectable in pretreatment tumor-biopsy specimens, the presence of the mutation correlated with reduced progression-free survival (7.7 mo vs. 16.5 mo, P < 0.001).  Serial anal. of circulating tumor cells showed that a redn. in the no. of captured cells was assocd. with a radiog. tumor response; an increase in the no. of cells was assocd. with tumor progression, with the emergence of addnl. EGFR mutations in some cases.  Conclusions: Mol. anal. of circulating tumor cells from the blood of patients with lung cancer offers the possibility of monitoring changes in epithelial tumor genotypes during the course of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLTOKkqtYuf7Vg90H21EOLACvtfcHk0lh-ulSdXydQgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFSqtbc%253D&md5=486f7f0595f77b80e72d508b690febf6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0800668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0800668%26sid%3Dliteratum%253Aachs%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DNagrath%26aufirst%3DS.%26aulast%3DUlkus%26aufirst%3DL.%26aulast%3DBrannigan%26aufirst%3DB.%26aulast%3DInserra%26aufirst%3DE.%26aulast%3DDiederichs%26aufirst%3DS.%26atitle%3DDetection%2520of%2520mutations%2520in%2520EGFR%2520in%2520circulating%2520lung-cancer%2520cells%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26spage%3D366%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Wenle, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spector, N. L.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of GW-572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6255</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=6255-6263&author=X.+Wenleauthor=R.+J.+Mullinauthor=B.+R.+Keithauthor=L.+H.+Liuauthor=H.+Maauthor=D.+W.+Rusnakauthor=G.+Owensauthor=K.+J.+Alligoodauthor=N.+L.+Spector&title=Anti-tumor+activity+of+GW-572016%3A+A+dual+tyrosine+kinase+inhibitor+blocks+EGF+activation+of+EGFR%2FerbB2+and+downstream+Erk1%2F2+and+AKT+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWenle%26aufirst%3DX.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DLiu%26aufirst%3DL.%2BH.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DOwens%26aufirst%3DG.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DSpector%26aufirst%3DN.%2BL.%26atitle%3DAnti-tumor%2520activity%2520of%2520GW-572016%253A%2520A%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520blocks%2520EGF%2520activation%2520of%2520EGFR%252FerbB2%2520and%2520downstream%2520Erk1%252F2%2520and%2520AKT%2520pathways%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D6255%26epage%3D6263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Johnston, S. R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leary, A.</span><span> </span><span class="NLM_article-title">Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1358%2Fdot.2006.42.7.985637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFamsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=441-453&author=S.+R.+D.+Johnstonauthor=A.+Leary&title=Lapatinib%3A+A+novel+EGFR%2FHER2+tyrosine+kinase+inhibitor+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer</span></div><div class="casAuthors">Johnston, Stephen R. D.; Leary, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">441-453</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Lapatinib is an oral dual tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2), both frequently overexpressed in human cancer.  Preclin. data have shown that lapatinib is a potent and selective inhibitor of the tyrosine kinase domain of EGFR and HER2, and tumor cells that overexpress these receptors are growth inhibited by lapatinib both in vitro and in vivo.  Phase I clin. trials have shown that lapatinib is well tolerated, with mild diarrhea and rash the most frequent toxicities, and early evidence of clin. efficacy has been reported esp. in HER2-pos. breast cancer.  Phase II studies have shown activity for lapatinib in trastuzumab-refractory breast cancer either alone or in combination with trastuzumab.  When used as first-line monotherapy for advanced breast cancer, objective tumor responses have been seen in 28% of patients with untreated HER2-pos. advanced breast cancer.  An extensive phase III program in advanced breast cancer is now in progress both for refractory disease and as first-line therapy in combination with chemotherapy with and without trastuzumab, and with endocrine therapy.  Phase II studies have also been conducted in a variety of other tumors, including renal cell cancer.  Parallel biomarker studies are starting to elucidate predictive mol. phenotypes that may indicate likelihood of response to lapatinib, and these may direct future trials with this oral tyrosine kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC9Obf0OXhBLVg90H21EOLACvtfcHk0lgJr6hlF1RFWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFamsLzO&md5=a1ebcf51ffa841d1fe058eebcc1e05fa</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1358%2Fdot.2006.42.7.985637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2006.42.7.985637%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26aulast%3DLeary%26aufirst%3DA.%26atitle%3DLapatinib%253A%2520A%2520novel%2520EGFR%252FHER2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520cancer%26jtitle%3DDrugs%2520Today%26date%3D2006%26volume%3D42%26spage%3D441%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reigh, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3958</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=R.+Nilakantanauthor=E.+Overbeekauthor=M.+F.+Reighauthor=R.+Shenauthor=X.+Shiauthor=H.+R.+Tsouauthor=Y.+F.+Wangauthor=A.+Wissner&title=Antitumor+activity+of+HKI-272%2C+an+orally+active%2C+irreversible+inhibitor+of+the+HER-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0lgsaUIV8fgx5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReigh%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520HKI-272%252C%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520HER-2%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.</span><span> </span><span class="NLM_article-title">Synthesis and structure−activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles: The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.+Wangauthor=L.+M.+Greenbergerauthor=H.+Tsou&title=Synthesis+and+structure%E2%88%92activity+relationships+of+6%2C7-disubstituted+4-anilinoquinoline-3-carbonitriles%3A+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinoline-3-carbonitriles%253A%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-<i>d</i>]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000372i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=429-440&author=J.+B.+Smaillauthor=H.+D.+H.+Showalterauthor=H.+Zhouauthor=A.+J.+Bridgesauthor=D.+J.+McNamaraauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=P.+W.+Vincentauthor=B.+J.+Robertsauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+18.+6-Substituted+4-anilinoquinazolines+and+4-anilinopyrido%5B3%2C4-d%5Dpyrimidines+as+soluble%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjm000372i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000372i%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252018.%25206-Substituted%25204-anilinoquinazolines%2520and%25204-anilinopyrido%255B3%252C4-d%255Dpyrimidines%2520as%2520soluble%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D429%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Campos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiden, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plante, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potkul, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldjian, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varterasian, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charbonneau, C.</span><span> </span><span class="NLM_article-title">Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5597</span><span class="NLM_x">–</span> <span class="NLM_lpage">5604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1200%2FJCO.2005.08.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=16110019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVersr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5597-5604&author=S.+Camposauthor=O.+Hamidauthor=M.+V.+Seidenauthor=A.+Ozaauthor=M.+Planteauthor=R.+K.+Potkulauthor=P.+F.+Lenehanauthor=E.+P.+Kaldjianauthor=M.+L.+Varterasianauthor=C.+Jordanauthor=C.+Charbonneau&title=Multicenter%2C+randomized+phase+II+trial+of+oral+CI-1033+for+previously+treated+advanced+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer</span></div><div class="casAuthors">Campos, Susana; Hamid, Oday; Seiden, Michael V.; Oza, Amit; Plante, Marie; Potkul, Ronald K.; Lenehan, Peter F.; Kaldjian, Eric P.; Varterasian, Mary L.; Jordan, Cheryl; Charbonneau, Claudie; Hirte, Hal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5597-5604</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To evaluate the antitumor activity and toxicity of two doses of CI-1033 in patients with platinum-refractory or recurrent ovarian cancer, and to det. baseline expression of epidermal growth factor receptor in tumor cells.  Patients and Methods: This phase II, open-label clin. trial evaluated CI-1033 in patients with ovarian cancer who failed prior platinum-based therapy.  Two oral doses of CI-1033 were evaluated-a 50-mg and a 200-mg oral dose administered daily for 21 days in a 28-day cycle.  Patients were evaluated for tumor response and toxicity; in addn., archival baseline tumor samples were analyzed by immunohistochem. for erbB1 to erbB4 status.  Results: One hundred five eligible patients were treated.  Baseline demog. characteristics were balanced in this heavily pretreated patient population.  The median no. of prior chemotherapy regimens received was four.  The most commonly encountered drug-related adverse events for both dose arms were gastrointestinal (diarrhea, nausea, stomatitis) toxicity, asthenia, and rash.  No responses were obsd.  Stable disease was confirmed in 34% and 26% of patients in the 200-mg and 50-mg arms, resp., and 1-yr survival rates were 38.5% and 37.7%, resp.  Baseline erbB3 and erbB4 revealed the highest frequencies of expression, while erbB2 was the lowest.  Conclusion: CI-1033 did not show activity in unscreened patients with advanced ovarian cancer.  At 50 mg/d, CI-1033 had a more favorable adverse events profile than at 200 mg/d.  ErbB3 and erbB4 receptors showed the highest expression in tumor samples while erbB2 revealed the least.  There appears to be no assocn. between baseline erbB expression and disease stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQbgq5slTwJLVg90H21EOLACvtfcHk0lgsaUIV8fgx5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVersr%252FL&md5=35cb9a35e064461ad1bbf3097ee09de8</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.08.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.08.091%26sid%3Dliteratum%253Aachs%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSeiden%26aufirst%3DM.%2BV.%26aulast%3DOza%26aufirst%3DA.%26aulast%3DPlante%26aufirst%3DM.%26aulast%3DPotkul%26aufirst%3DR.%2BK.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DKaldjian%26aufirst%3DE.%2BP.%26aulast%3DVarterasian%26aufirst%3DM.%2BL.%26aulast%3DJordan%26aufirst%3DC.%26aulast%3DCharbonneau%26aufirst%3DC.%26atitle%3DMulticenter%252C%2520randomized%2520phase%2520II%2520trial%2520of%2520oral%2520CI-1033%2520for%2520previously%2520treated%2520advanced%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5597%26epage%3D5604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+Correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0ljOAvlg4wcX9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520Correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Yun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0ljOAvlg4wcX9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small+cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljOAvlg4wcX9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small%2520cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">7096</span><span class="NLM_x">–</span> <span class="NLM_lpage">7101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=7096-7101&author=S.+Kobayashiauthor=H.+Jiauthor=Y.+Yuzaauthor=M.+Meyersonauthor=K.+K.+Wongauthor=D.+G.+Tenenauthor=B.+Halmos&title=An+alternative+inhibitor+overcomes+resistance+caused+by+a+mutation+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DAn%2520alternative%2520inhibitor%2520overcomes%2520resistance%2520caused%2520by%2520a%2520mutation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D7096%26epage%3D7101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, An irreversible pan-ERBB inhibitor, is effective in lung cancer models with <i>EGFR</i> and <i>ERBB2</i> mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.+M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.+K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+An+irreversible+pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520An%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Shintani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crohin, C. C.</span><span> </span><span class="NLM_article-title">Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">4142</span><span class="NLM_x">–</span> <span class="NLM_lpage">4147</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=4142-4147&author=S.+Shintaniauthor=K.+Matsuoauthor=C.+C.+Crohin&title=Intragenic+mutation+analysis+of+the+human+epidermal+growth+factor+receptor+%28EGFR%29+gene+in+malignant+human+oral+keratinocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShintani%26aufirst%3DS.%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DCrohin%26aufirst%3DC.%2BC.%26atitle%3DIntragenic%2520mutation%2520analysis%2520of%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520gene%2520in%2520malignant%2520human%2520oral%2520keratinocytes%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D4142%26epage%3D4147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Wildenhain, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrulis, I. L.</span><span> </span><span class="NLM_article-title">p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">883</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1990&pages=879-883&author=Y.+Wildenhainauthor=T.+Pawsonauthor=M.+E.+Blacksteinauthor=I.+L.+Andrulis&title=p185neu+is+phosphorylated+on+tyrosine+in+human+primary+breast+tumors+which+overexpress+neu%2FerbB-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWildenhain%26aufirst%3DY.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DAndrulis%26aufirst%3DI.%2BL.%26atitle%3Dp185neu%2520is%2520phosphorylated%2520on%2520tyrosine%2520in%2520human%2520primary%2520breast%2520tumors%2520which%2520overexpress%2520neu%252FerbB-2%26jtitle%3DOncogene%26date%3D1990%26volume%3D5%26spage%3D879%26epage%3D883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">7096</span><span class="NLM_x">–</span> <span class="NLM_lpage">7101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=7096-7101&author=S.+Kobayashiauthor=H.+Jiauthor=Y.+Yuzaauthor=M.+Meyersonauthor=K.+Wongauthor=D.+G.+Tenenauthor=B.+Halmos&title=An+alternative+inhibitor+overcomes+resistance+caused+by+a+mutation+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DAn%2520alternative%2520inhibitor%2520overcomes%2520resistance%2520caused%2520by%2520a%2520mutation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D7096%26epage%3D7101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="note"><p class="first last">Inhibition rate (%) = (1 − relative tumor growth in treated group/relative tumor growth in control group) × 100.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lee, K.-O.; Gong, J. H.; Cha, M. Y.; Lee, C. G.; Kim, Y. H.; Lee, K.; Song, T. H.; Song, J. Y.; Park, Y.-J.; Kim, E. Y.; Lee, E.; Lee, K.; Kim, M. S.; Lee, G. S.</span><span> </span><span class="NLM_article-title">Quinazoline derivatives for inhibiting the growth of cancer cell</span>. PCT Int. Appl. WO2008002039A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.-O.+Lee&author=J.+H.+Gong&author=M.+Y.+Cha&author=C.+G.+Lee&author=Y.+H.+Kim&author=K.+Lee&author=T.+H.+Song&author=J.+Y.+Song&author=Y.-J.+Park&author=E.+Y.+Kim&author=E.+Lee&author=K.+Lee&author=M.+S.+Kim&author=G.+S.+Lee&title=Quinazoline+derivatives+for+inhibiting+the+growth+of+cancer+cell"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.-O.%26atitle%3DQuinazoline%2520derivatives%2520for%2520inhibiting%2520the%2520growth%2520of%2520cancer%2520cell%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ham, Y. J.; Gong, J. H.; Cha, M. Y.; Kim, J. W.; Kim, M. S.; Kim, E. Y.; Song, J. Y.; Kim, C. I.; Kim, S. Y.; Lee, G. S.</span><span> </span><span class="NLM_article-title">Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof</span>. PCT Int. Appl. WO2006071017A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=Y.+J.+Ham&author=J.+H.+Gong&author=M.+Y.+Cha&author=J.+W.+Kim&author=M.+S.+Kim&author=E.+Y.+Kim&author=J.+Y.+Song&author=C.+I.+Kim&author=S.+Y.+Kim&author=G.+S.+Lee&title=Quinazoline+derivatives+for+inhibiting+cancer+cell+growth+and+method+for+the+preparation+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHam%26aufirst%3DY.%2BJ.%26atitle%3DQuinazoline%2520derivatives%2520for%2520inhibiting%2520cancer%2520cell%2520growth%2520and%2520method%2520for%2520the%2520preparation%2520thereof%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gong, J. H.; Cha, M. Y.; Kim, J. W.; Lee, C. G.; Kim, S. Y.; Lee, K.-O.; Kim, M. S.; Kim, H. K.; Lim, C. K.; Kim, Y. H.; Lee, G. S.</span><span> </span><span class="NLM_article-title">Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof</span>. PCT Int. Appl. WO2006071079A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+H.+Gong&author=M.+Y.+Cha&author=J.+W.+Kim&author=C.+G.+Lee&author=S.+Y.+Kim&author=K.-O.+Lee&author=M.+S.+Kim&author=H.+K.+Kim&author=C.+K.+Lim&author=Y.+H.+Kim&author=G.+S.+Lee&title=Quinazoline+derivatives+for+inhibiting+cancer+cell+growth+and+method+for+the+preparation+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%2BH.%26atitle%3DQuinazoline%2520derivatives%2520for%2520inhibiting%2520cancer%2520cell%2520growth%2520and%2520method%2520for%2520the%2520preparation%2520thereof%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="note"><p class="first last">A431 cell washout test. A431 cells were incubated in 6-well plates to the extent of 500000 cells/well for 24 h. One set of cells were treated with 1 μM of <b>2</b> (Erlotinib) and the other set of cells were treated with 1 μM of analog <b>19c</b> for 4 h. Each set was washed four times with warmed compound-free medium and incubated for 8 h. Each set was simulated with EGF (100 ng/mL) for 5 min. The phosphorylation rate of EGFR was measured by Western blot. From this experiment, compound <b>19c</b> showed significant less phosphorylation rate (15%) of EGFR than <b>2</b> (100% phosphorylation). This result suggests that compound <b>19c</b> has an irreversible binding mode.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last"><i>V</i> = <i>L</i> × <i>S</i><sup>2</sup>/2 (<i>V</i>, tumor volume in milligrams; <i>L</i>, long diameter; <i>S</i>, short diameter).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':[],'ref24':['cit24a','cit24b','cit24c'],'ref25':[],'ref26':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 29 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Andrea J.  Gonzales</span>, <span class="hlFld-ContribAuthor ">Julie A.  Spicer</span>, <span class="hlFld-ContribAuthor ">Helen  Lee</span>, <span class="hlFld-ContribAuthor ">Jessica E.  Reed</span>, <span class="hlFld-ContribAuthor ">Karen  Sexton</span>, <span class="hlFld-ContribAuthor ">Irene W.  Althaus</span>, <span class="hlFld-ContribAuthor ">Tong  Zhu</span>, <span class="hlFld-ContribAuthor ">Shannon L.  Black</span>, <span class="hlFld-ContribAuthor ">Adrian  Blaser</span>, <span class="hlFld-ContribAuthor ">William A.  Denny</span>, <span class="hlFld-ContribAuthor ">Paul A.  Ellis</span>, <span class="hlFld-ContribAuthor ">Stephen  Fakhoury</span>, <span class="hlFld-ContribAuthor ">Patricia J.  Harvey</span>, <span class="hlFld-ContribAuthor ">Ken  Hook</span>, <span class="hlFld-ContribAuthor ">Florence O. J.  McCarthy</span>, <span class="hlFld-ContribAuthor ">Brian D.  Palmer</span>, <span class="hlFld-ContribAuthor ">Freddy  Rivault</span>, <span class="hlFld-ContribAuthor ">Kevin  Schlosser</span>, <span class="hlFld-ContribAuthor ">Teresa  Ellis</span>, <span class="hlFld-ContribAuthor ">Andrew M.  Thompson</span>, <span class="hlFld-ContribAuthor ">Erin  Trachet</span>, <span class="hlFld-ContribAuthor ">R. Thomas  Winters</span>, <span class="hlFld-ContribAuthor ">Haile  Tecle</span>, and <span class="hlFld-ContribAuthor ">Alexander  Bridges</span>  . </span><span class="cited-content_cbyCitation_article-title">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (17)
                                     , 8103-8124. <a href="https://doi.org/10.1021/acs.jmedchem.6b00883" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00883</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTyrosine%252BKinase%252BInhibitors.%252B20.%252BOptimization%252Bof%252BSubstituted%252BQuinazoline%252Band%252BPyrido%25255B3%25252C4-d%25255Dpyrimidine%252BDerivatives%252Bas%252BOrally%252BActive%25252C%252BIrreversible%252BInhibitors%252Bof%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BFamily%26aulast%3DSmaill%26aufirst%3DJeff%2BB.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D15062016%26date%3D22082016%26date%3D08092016%26date%3D04082016%26volume%3D59%26issue%3D17%26spage%3D8103%26epage%3D8124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Jessica E.    Reed </span><span class="hlFld-ContribAuthor "> Jeff B.    Smaill </span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 207-233. <a href="https://doi.org/10.1021/bk-2016-1239.ch008" title="DOI URL">https://doi.org/10.1021/bk-2016-1239.ch008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2016-1239.ch008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2016-1239.ch008%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDiscovery%252Bof%252BDacomitinib%25252C%252Ba%252BPotent%252BIrreversible%252BEGFR%252BInhibitor%26aulast%3DReed%26aufirst%3DJessica%2BE.%26date%3D2016%26date%3D2016%26spage%3D207%26epage%3D233%26atitle%3DComprehensive%252BAccounts%252Bof%252BPharmaceutical%252BResearch%252Band%252BDevelopment%25253A%252BFrom%252BDiscovery%252Bto%252BLate-Stage%252BProcess%252BDevelopment%252BVolume%252B1%26aulast%3DAbdel-Magid%26aufirst%3DAhmed%2BF.%26date%3D2016%26date%3D2016%26volume%3D1239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mu  Yang</span>, <span class="hlFld-ContribAuthor ">Amanda J.  Pickard</span>, <span class="hlFld-ContribAuthor ">Xin  Qiao</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Gueble</span>, <span class="hlFld-ContribAuthor ">Cynthia S.  Day</span>, <span class="hlFld-ContribAuthor ">Gregory L.  Kucera</span>, and <span class="hlFld-ContribAuthor ">Ulrich  Bierbach</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis, Reactivity, and Biological Activity of Gold(I) Complexes Modified with Thiourea-Functionalized Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2015,</strong> <em>54 </em>
                                    (7)
                                     , 3316-3324. <a href="https://doi.org/10.1021/ic502998a" title="DOI URL">https://doi.org/10.1021/ic502998a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ic502998a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fic502998a%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DSynthesis%25252C%252BReactivity%25252C%252Band%252BBiological%252BActivity%252Bof%252BGold%252528I%252529%252BComplexes%252BModified%252Bwith%252BThiourea-Functionalized%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DYang%26aufirst%3DMu%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D17122014%26date%3D20032015%26date%3D06042015%26volume%3D54%26issue%3D7%26spage%3D3316%26epage%3D3324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongqiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Shengzheng  Wang</span>, <span class="hlFld-ContribAuthor ">Shanchao  Wu</span>, <span class="hlFld-ContribAuthor ">Shiping  Zhu</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Zhenyuan  Miao</span>, <span class="hlFld-ContribAuthor ">Jianzhong  Yao</span>, <span class="hlFld-ContribAuthor ">Wannian  Zhang</span>, <span class="hlFld-ContribAuthor ">Chunquan  Sheng</span>, and <span class="hlFld-ContribAuthor ">Wei  Wang</span>  . </span><span class="cited-content_cbyCitation_article-title">Facile Construction of Structurally Diverse Thiazolidinedione-Derived Compounds via Divergent Stereoselective Cascade Organocatalysis and Their Biological Exploratory Studies. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2013,</strong> <em>15 </em>
                                    (6)
                                     , 298-308. <a href="https://doi.org/10.1021/co400022r" title="DOI URL">https://doi.org/10.1021/co400022r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/co400022r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fco400022r%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DFacile%252BConstruction%252Bof%252BStructurally%252BDiverse%252BThiazolidinedione-Derived%252BCompounds%252Bvia%252BDivergent%252BStereoselective%252BCascade%252BOrganocatalysis%252Band%252BTheir%252BBiological%252BExploratory%252BStudies%26aulast%3DZhang%26aufirst%3DYongqiang%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D18022013%26date%3D15042013%26date%3D08052013%26date%3D10062013%26date%3D24042013%26volume%3D15%26issue%3D6%26spage%3D298%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tjeerd  Barf</span> and <span class="hlFld-ContribAuthor ">Allard  Kaptein</span>  . </span><span class="cited-content_cbyCitation_article-title">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (14)
                                     , 6243-6262. <a href="https://doi.org/10.1021/jm3003203" title="DOI URL">https://doi.org/10.1021/jm3003203</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm3003203%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIrreversible%252BProtein%252BKinase%252BInhibitors%25253A%252BBalancing%252Bthe%252BBenefits%252Band%252BRisks%26aulast%3DBarf%26aufirst%3DTjeerd%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D07032012%26date%3D08062012%26date%3D26072012%26date%3D23052012%26volume%3D55%26issue%3D14%26spage%3D6243%26epage%3D6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaohua  Chang</span>, <span class="hlFld-ContribAuthor ">Lianwen  Zhang</span>, <span class="hlFld-ContribAuthor ">Shilin  Xu</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Yingxue  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengchao  Tu</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Duanqing  Pei</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (6)
                                     , 2711-2723. <a href="https://doi.org/10.1021/jm201591k" title="DOI URL">https://doi.org/10.1021/jm201591k</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201591k%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BConformationally%252BConstrained%252BInhibitors%252BTargeting%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BThreonine790%252B%2525E2%252586%252592%252BMethionine790%252BMutant%26aulast%3DChang%26aufirst%3DShaohua%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D25112011%26date%3D01032012%26date%3D22032012%26date%3D16022012%26volume%3D55%26issue%3D6%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mi Young  Cha</span>, <span class="hlFld-ContribAuthor ">Kwang-Ok  Lee</span>, <span class="hlFld-ContribAuthor ">Seok-Jong  Kang</span>, <span class="hlFld-ContribAuthor ">Young Hee  Jung</span>, <span class="hlFld-ContribAuthor ">Ji Yeon  Song</span>, <span class="hlFld-ContribAuthor ">Kyung Jin  Choi</span>, <span class="hlFld-ContribAuthor ">Joo Yun  Byun</span>, <span class="hlFld-ContribAuthor ">Han-Jae  Lee</span>, <span class="hlFld-ContribAuthor ">Gwan Sun  Lee</span>, <span class="hlFld-ContribAuthor ">Seung Bum  Park</span>, and <span class="hlFld-ContribAuthor ">Maeng Sup  Kim</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis and Biological Evaluation of Pyrimidine-Based Dual Inhibitors of Human Epidermal Growth Factor Receptor 1 (HER-1) and HER-2 Tyrosine Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (6)
                                     , 2846-2857. <a href="https://doi.org/10.1021/jm201758g" title="DOI URL">https://doi.org/10.1021/jm201758g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm201758g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm201758g%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BPyrimidine-Based%252BDual%252BInhibitors%252Bof%252BHuman%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B1%252B%252528HER-1%252529%252Band%252BHER-2%252BTyrosine%252BKinases%26aulast%3DCha%26aufirst%3DMi%2BYoung%26date%3D2012%26date%3D2012%26date%3D2011%26date%3D30122011%26date%3D09032012%26date%3D22032012%26date%3D28022012%26volume%3D55%26issue%3D6%26spage%3D2846%26epage%3D2857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emeline  Leproult</span>, <span class="hlFld-ContribAuthor ">Sofia  Barluenga</span>, <span class="hlFld-ContribAuthor ">Dino  Moras</span>, <span class="hlFld-ContribAuthor ">Jean-Marie  Wurtz</span>, and <span class="hlFld-ContribAuthor ">Nicolas  Winssinger</span>  . </span><span class="cited-content_cbyCitation_article-title">Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>54 </em>
                                    (5)
                                     , 1347-1355. <a href="https://doi.org/10.1021/jm101396q" title="DOI URL">https://doi.org/10.1021/jm101396q</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm101396q%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCysteine%252BMapping%252Bin%252BConformationally%252BDistinct%252BKinase%252BNucleotide%252BBinding%252BSites%25253A%252BApplication%252Bto%252Bthe%252BDesign%252Bof%252BSelective%252BCovalent%252BInhibitors%26aulast%3DLeproult%26aufirst%3DEmeline%26date%3D2011%26date%3D2011%26date%3D2010%26date%3D28102010%26date%3D15022011%26date%3D10032011%26volume%3D54%26issue%3D5%26spage%3D1347%26epage%3D1355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaitlyn A.  Maffuid</span>, <span class="hlFld-ContribAuthor ">Maria  Koyioni</span>, <span class="hlFld-ContribAuthor ">Chad D.  Torrice</span>, <span class="hlFld-ContribAuthor ">William A.  Murphy</span>, <span class="hlFld-ContribAuthor ">Heemaja K.  Mewada</span>, <span class="hlFld-ContribAuthor ">Panayiotis A.  Koutentis</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Crona</span>, <span class="hlFld-ContribAuthor ">Christopher R.M.  Asquith</span>. </span><span class="cited-content_cbyCitation_article-title">Design and evaluation of 1,2,3-dithiazoles and fused 1,2,4-dithiazines as anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>43 </em>, 128078. <a href="https://doi.org/10.1016/j.bmcl.2021.128078" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128078%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bevaluation%252Bof%252B1%25252C2%25252C3-dithiazoles%252Band%252Bfused%252B1%25252C2%25252C4-dithiazines%252Bas%252Banti-cancer%252Bagents%26aulast%3DMaffuid%26aufirst%3DKaitlyn%2BA.%26date%3D2021%26volume%3D43%26spage%3D128078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuai  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-Han  Yuan</span>, <span class="hlFld-ContribAuthor ">Sai-Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Wen  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiao-Bing  Chen</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113218. <a href="https://doi.org/10.1016/j.ejmech.2021.113218" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113218</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113218%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFDA-approved%252Bpyrimidine-fused%252Bbicyclic%252Bheterocycles%252Bfor%252Bcancer%252Btherapy%25253A%252BSynthesis%252Band%252Bclinical%252Bapplication%26aulast%3DWang%26aufirst%3DShuai%26date%3D2021%26volume%3D214%26spage%3D113218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Inhwan  Bae</span>, <span class="hlFld-ContribAuthor ">Daejin  Kim</span>, <span class="hlFld-ContribAuthor ">Jaeyul  Choi</span>, <span class="hlFld-ContribAuthor ">Jisook  Kim</span>, <span class="hlFld-ContribAuthor ">Minjeong  Kim</span>, <span class="hlFld-ContribAuthor ">Bokyung  Park</span>, <span class="hlFld-ContribAuthor ">Young Hoon  Kim</span>, <span class="hlFld-ContribAuthor ">Young Gil  Ahn</span>, <span class="hlFld-ContribAuthor ">Ha  Hyung Kim</span>, <span class="hlFld-ContribAuthor ">Dae Kyong  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of new bivalent quinazoline analogues as IAP antagonists. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>34 </em>, 127676. <a href="https://doi.org/10.1016/j.bmcl.2020.127676" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127676</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127676%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnew%252Bbivalent%252Bquinazoline%252Banalogues%252Bas%252BIAP%252Bantagonists%26aulast%3DBae%26aufirst%3DInhwan%26date%3D2021%26volume%3D34%26spage%3D127676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Li</span>, <span class="hlFld-ContribAuthor ">Jie  Xiao</span>, <span class="hlFld-ContribAuthor ">Qizhi  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenmei  Yu</span>, <span class="hlFld-ContribAuthor ">Mengqin  Liu</span>, <span class="hlFld-ContribAuthor ">Yu  Guo</span>, <span class="hlFld-ContribAuthor ">Jun  He</span>, <span class="hlFld-ContribAuthor ">Yunmei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (3)
                                     , 568-577. <a href="https://doi.org/10.1016/j.bmc.2018.12.032" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.12.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.12.032%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bassociation%252Bbetween%252Banti-tumor%252Bpotency%252Band%252Bstructure-activity%252Bof%252Bprotein-kinases%252Binhibitors%252Bbased%252Bon%252Bquinazoline%252Bmolecular%252Bskeleton%26aulast%3DLi%26aufirst%3DYang%26date%3D2019%26volume%3D27%26issue%3D3%26spage%3D568%26epage%3D577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra N.  Milik</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 131-151. <a href="https://doi.org/10.1016/j.ejmech.2017.07.023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.07.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.07.023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHow%252Bto%252Btrain%252Byour%252Binhibitor%25253A%252BDesign%252Bstrategies%252Bto%252Bovercome%252Bresistance%252Bto%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252Binhibitors%26aulast%3DMilik%26aufirst%3DSandra%2BN.%26date%3D2017%26volume%3D142%26spage%3D131%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.  Qu</span>, <span class="hlFld-ContribAuthor ">A.  Yan</span>, <span class="hlFld-ContribAuthor ">J. S.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2017,</strong> <em>28 </em>
                                    (2)
                                     , 111-132. <a href="https://doi.org/10.1080/1062936X.2017.1284898" title="DOI URL">https://doi.org/10.1080/1062936X.2017.1284898</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2017.1284898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2017.1284898%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DSAR%252Band%252BQSAR%252Bstudy%252Bon%252Bthe%252Bbioactivities%252Bof%252Bhuman%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor-2%252B%252528HER2%252529%252Binhibitors%26aulast%3DQu%26aufirst%3DD.%26date%3D2017%26date%3D2017%26volume%3D28%26issue%3D2%26spage%3D111%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pankaj Kumar  Singh</span>, <span class="hlFld-ContribAuthor ">Harpreet  Singh</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Kinases inhibitors in lung cancer: From benchside to bedside. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</span><span> <strong>2016,</strong> <em>1866 </em>
                                    (1)
                                     , 128-140. <a href="https://doi.org/10.1016/j.bbcan.2016.07.002" title="DOI URL">https://doi.org/10.1016/j.bbcan.2016.07.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbcan.2016.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbcan.2016.07.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Reviews%2520on%2520Cancer%26atitle%3DKinases%252Binhibitors%252Bin%252Blung%252Bcancer%25253A%252BFrom%252Bbenchside%252Bto%252Bbedside%26aulast%3DSingh%26aufirst%3DPankaj%2BKumar%26date%3D2016%26volume%3D1866%26issue%3D1%26spage%3D128%26epage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">R.  Balajee</span>, <span class="hlFld-ContribAuthor ">V.  Srinivasadesikan</span>, <span class="hlFld-ContribAuthor ">M.  Sakthivadivel</span>, <span class="hlFld-ContribAuthor ">P.  Gunasekaran</span>. </span><span class="cited-content_cbyCitation_article-title">In Silico
              Screening, Alanine Mutation, and DFT Approaches for Identification of NS2B/NS3 Protease Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry Research International</span><span> <strong>2016,</strong> <em>2016 </em>, 1-13. <a href="https://doi.org/10.1155/2016/7264080" title="DOI URL">https://doi.org/10.1155/2016/7264080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2016/7264080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2016%2F7264080%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%2520Research%2520International%26atitle%3DIn%252BSilico%252BScreening%25252C%252BAlanine%252BMutation%25252C%252Band%252BDFT%252BApproaches%252Bfor%252BIdentification%252Bof%252BNS2B%25252FNS3%252BProtease%252BInhibitors%26aulast%3DBalajee%26aufirst%3DR.%26date%3D2016%26volume%3D2016%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Styliana I.  Mirallai</span>, <span class="hlFld-ContribAuthor ">Maria  Manoli</span>, <span class="hlFld-ContribAuthor ">Panayiotis A.  Koutentis</span>. </span><span class="cited-content_cbyCitation_article-title">The reaction of 2-amino- N ′-arylbenzamidines with tetracyanoethene reinvestigated: routes to imidazoles, quinazolines and quinolino[2′,3′:4,5]imidazo[1,2- c ]quinazoline-8-carbonitrile. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2015,</strong> <em>71 </em>
                                    (46)
                                     , 8766-8780. <a href="https://doi.org/10.1016/j.tet.2015.09.049" title="DOI URL">https://doi.org/10.1016/j.tet.2015.09.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2015.09.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2015.09.049%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DThe%252Breaction%252Bof%252B2-amino-%252BN%252B%2525E2%252580%2525B2-arylbenzamidines%252Bwith%252Btetracyanoethene%252Breinvestigated%25253A%252Broutes%252Bto%252Bimidazoles%25252C%252Bquinazolines%252Band%252Bquinolino%25255B2%2525E2%252580%2525B2%25252C3%2525E2%252580%2525B2%25253A4%25252C5%25255Dimidazo%25255B1%25252C2-%252Bc%252B%25255Dquinazoline-8-carbonitrile%26aulast%3DMirallai%26aufirst%3DStyliana%2BI.%26date%3D2015%26volume%3D71%26issue%3D46%26spage%3D8766%26epage%3D8780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sun-Young  Jang</span>, <span class="hlFld-ContribAuthor ">Seul  Lee</span>, <span class="hlFld-ContribAuthor ">Mira  Kim</span>, <span class="hlFld-ContribAuthor ">Young Jin  Ham</span>, <span class="hlFld-ContribAuthor ">Mi Young  Cha</span>, <span class="hlFld-ContribAuthor ">Kwee Hyun  Suh</span>, <span class="hlFld-ContribAuthor ">Young Hoon  Kim</span>, <span class="hlFld-ContribAuthor ">Ara  Kwon</span>, <span class="hlFld-ContribAuthor ">Hae Ju  Kang</span>, <span class="hlFld-ContribAuthor ">Kyung Hoon  Min</span>, <span class="hlFld-ContribAuthor ">Kwang-Ok  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Quinazoline Analogues with Differential Activity for HER2-overexpressing Breast Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2015,</strong> <em>36 </em>
                                    (7)
                                     , 1933-1935. <a href="https://doi.org/10.1002/bkcs.10358" title="DOI URL">https://doi.org/10.1002/bkcs.10358</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bkcs.10358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbkcs.10358%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DSynthesis%252Bof%252BQuinazoline%252BAnalogues%252Bwith%252BDifferential%252BActivity%252Bfor%252BHER2-overexpressing%252BBreast%252BCancer%252BCells%26aulast%3DJang%26aufirst%3DSun-Young%26date%3D2015%26date%3D2015%26volume%3D36%26issue%3D7%26spage%3D1933%26epage%3D1935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edward L  Nelson</span>. </span><span class="cited-content_cbyCitation_article-title">HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations. </span><span class="cited-content_cbyCitation_journal-name">Clinical Investigation</span><span> <strong>2014,</strong> <em>4 </em>
                                    (9)
                                     , 791-823. <a href="https://doi.org/10.4155/cli.14.63" title="DOI URL">https://doi.org/10.4155/cli.14.63</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/cli.14.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fcli.14.63%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Investigation%26atitle%3DHER2%25252Fneu%25253A%252Ban%252Bincreasingly%252Bimportant%252Btherapeutic%252Btarget.%252BPart%252B3%25253A%252Bclinical%252Bapplications%252Band%252Binvestigations%26aulast%3DNelson%26aufirst%3DEdward%2BL%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D791%26epage%3D823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Ridong  Li</span>, <span class="hlFld-ContribAuthor ">Kang  Qiao</span>, <span class="hlFld-ContribAuthor ">Zemei  Ge</span>, <span class="hlFld-ContribAuthor ">Liangren  Zhang</span>, <span class="hlFld-ContribAuthor ">Tieming  Cheng</span>, <span class="hlFld-ContribAuthor ">Runtao  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Dithiocarbamic Acid Esters Derived from 6-Aminomethyl-4-anilinoquinazolines and 6-Aminomethyl-4-anilino-3-cyanoquinolines as Potent EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2013,</strong> <em>346 </em>
                                    (1)
                                     , 44-52. <a href="https://doi.org/10.1002/ardp.201200267" title="DOI URL">https://doi.org/10.1002/ardp.201200267</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201200267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201200267%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DNovel%252BDithiocarbamic%252BAcid%252BEsters%252BDerived%252Bfrom%252B6-Aminomethyl-4-anilinoquinazolines%252Band%252B6-Aminomethyl-4-anilino-3-cyanoquinolines%252Bas%252BPotent%252BEGFR%252BInhibitors%26aulast%3DZhang%26aufirst%3DXin%26date%3D2013%26date%3D2012%26volume%3D346%26issue%3D1%26spage%3D44%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S  Yoshikawa</span>, <span class="hlFld-ContribAuthor ">M  Kukimoto-Niino</span>, <span class="hlFld-ContribAuthor ">L  Parker</span>, <span class="hlFld-ContribAuthor ">N  Handa</span>, <span class="hlFld-ContribAuthor ">T  Terada</span>, <span class="hlFld-ContribAuthor ">T  Fujimoto</span>, <span class="hlFld-ContribAuthor ">Y  Terazawa</span>, <span class="hlFld-ContribAuthor ">M  Wakiyama</span>, <span class="hlFld-ContribAuthor ">M  Sato</span>, <span class="hlFld-ContribAuthor ">S  Sano</span>, <span class="hlFld-ContribAuthor ">T  Kobayashi</span>, <span class="hlFld-ContribAuthor ">T  Tanaka</span>, <span class="hlFld-ContribAuthor ">L  Chen</span>, <span class="hlFld-ContribAuthor ">Z-J  Liu</span>, <span class="hlFld-ContribAuthor ">B-C  Wang</span>, <span class="hlFld-ContribAuthor ">M  Shirouzu</span>, <span class="hlFld-ContribAuthor ">S  Kawa</span>, <span class="hlFld-ContribAuthor ">K  Semba</span>, <span class="hlFld-ContribAuthor ">T  Yamamoto</span>, <span class="hlFld-ContribAuthor ">S  Yokoyama</span>. </span><span class="cited-content_cbyCitation_article-title">Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2013,</strong> <em>32 </em>
                                    (1)
                                     , 27-38. <a href="https://doi.org/10.1038/onc.2012.21" title="DOI URL">https://doi.org/10.1038/onc.2012.21</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/onc.2012.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fonc.2012.21%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DStructural%252Bbasis%252Bfor%252Bthe%252Baltered%252Bdrug%252Bsensitivities%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer-associated%252Bmutants%252Bof%252Bhuman%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%26aulast%3DYoshikawa%26aufirst%3DS%26date%3D2013%26date%3D2012%26volume%3D32%26issue%3D1%26spage%3D27%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena  Galvani</span>, <span class="hlFld-ContribAuthor ">Elisa  Giovannetti</span>, <span class="hlFld-ContribAuthor ">Francesca  Saccani</span>, <span class="hlFld-ContribAuthor ">Andrea  Cavazzoni</span>, <span class="hlFld-ContribAuthor ">Leticia G.  Leon</span>, <span class="hlFld-ContribAuthor ">Henk  Dekker</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>, <span class="hlFld-ContribAuthor ">Caterina  Carmi</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Andrea  Ardizzoni</span>, <span class="hlFld-ContribAuthor ">Pier Giorgio  Petronini</span>, <span class="hlFld-ContribAuthor ">Godefridus J.  Peters</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Neoplasia</span><span> <strong>2013,</strong> <em>15 </em>
                                    (1)
                                     , 61-IN18. <a href="https://doi.org/10.1593/neo.121434" title="DOI URL">https://doi.org/10.1593/neo.121434</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1593/neo.121434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1593%2Fneo.121434%26sid%3Dliteratum%253Aachs%26jtitle%3DNeoplasia%26atitle%3DMolecular%252BMechanisms%252BUnderlying%252Bthe%252BAntitumor%252BActivity%252Bof%252B3-Aminopropanamide%252BIrreversible%252BInhibitors%252Bof%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252Bin%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%26aulast%3DGalvani%26aufirst%3DElena%26date%3D2013%26volume%3D15%26issue%3D1%26spage%3D61%26epage%3DIN18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">He Ping  Yan</span>, <span class="hlFld-ContribAuthor ">Du Shu  Huang</span>, <span class="hlFld-ContribAuthor ">Ju Cheng  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of 4-(3′-Chlorophenylamino)-6-Methoxy Quinazoline Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Advanced Materials Research</span><span> <strong>2013,</strong> <em>634-638 </em>, 1215-1218. <a href="https://doi.org/10.4028/www.scientific.net/AMR.634-638.1215" title="DOI URL">https://doi.org/10.4028/www.scientific.net/AMR.634-638.1215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4028/www.scientific.net/AMR.634-638.1215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4028%2Fwww.scientific.net%2FAMR.634-638.1215%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Materials%2520Research%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252B4-%2525283%2525E2%252580%2525B2-Chlorophenylamino%252529-6-Methoxy%252BQuinazoline%252BDerivatives%26aulast%3DYan%26aufirst%3DHe%2BPing%26date%3D2013%26date%3D2013%26volume%3D634-638%26spage%3D1215%26epage%3D1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mi Young  Cha</span>, <span class="hlFld-ContribAuthor ">Kwang-Ok  Lee</span>, <span class="hlFld-ContribAuthor ">Mira  Kim</span>, <span class="hlFld-ContribAuthor ">Ji Yeon  Song</span>, <span class="hlFld-ContribAuthor ">Kyu Hang  Lee</span>, <span class="hlFld-ContribAuthor ">Jongmin  Park</span>, <span class="hlFld-ContribAuthor ">Yun Jung  Chae</span>, <span class="hlFld-ContribAuthor ">Young Hoon  Kim</span>, <span class="hlFld-ContribAuthor ">Kwee Hyun  Suh</span>, <span class="hlFld-ContribAuthor ">Gwan Sun  Lee</span>, <span class="hlFld-ContribAuthor ">Seung Bum  Park</span>, <span class="hlFld-ContribAuthor ">Maeng Sup  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Cancer</span><span> <strong>2012,</strong> <em>130 </em>
                                    (10)
                                     , 2445-2454. <a href="https://doi.org/10.1002/ijc.26276" title="DOI URL">https://doi.org/10.1002/ijc.26276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ijc.26276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fijc.26276%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Cancer%26atitle%3DAntitumor%252Bactivity%252Bof%252BHM781-36B%25252C%252Ba%252Bhighly%252Beffective%252Bpan-HER%252Binhibitor%252Bin%252Berlotinib-resistant%252BNSCLC%252Band%252Bother%252BEGFR-dependent%252Bcancer%252Bmodels%26aulast%3DCha%26aufirst%3DMi%2BYoung%26date%3D2012%26date%3D2011%26volume%3D130%26issue%3D10%26spage%3D2445%26epage%3D2454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giovanni  Marzaro</span>, <span class="hlFld-ContribAuthor ">Adriano  Guiotto</span>, <span class="hlFld-ContribAuthor ">Adriana  Chilin</span>. </span><span class="cited-content_cbyCitation_article-title">Quinazoline derivatives as potential anticancer agents: a patent review (2007 – 2010). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2012,</strong> <em>22 </em>
                                    (3)
                                     , 223-252. <a href="https://doi.org/10.1517/13543776.2012.665876" title="DOI URL">https://doi.org/10.1517/13543776.2012.665876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2012.665876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2012.665876%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DQuinazoline%252Bderivatives%252Bas%252Bpotential%252Banticancer%252Bagents%25253A%252Ba%252Bpatent%252Breview%252B%2525282007%252B%2525E2%252580%252593%252B2010%252529%26aulast%3DMarzaro%26aufirst%3DGiovanni%26date%3D2012%26date%3D2012%26volume%3D22%26issue%3D3%26spage%3D223%26epage%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">María  Font</span>, <span class="hlFld-ContribAuthor ">Álvaro  González</span>, <span class="hlFld-ContribAuthor ">Juan Antonio  Palop</span>, <span class="hlFld-ContribAuthor ">Carmen  Sanmartín</span>. </span><span class="cited-content_cbyCitation_article-title">New insights into the structural requirements for pro-apoptotic agents based on 2,4-diaminoquinazoline, 2,4-diaminopyrido[2,3-d]pyrimidine and 2,4-diaminopyrimidine derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2011,</strong> <em>46 </em>
                                    (9)
                                     , 3887-3899. <a href="https://doi.org/10.1016/j.ejmech.2011.05.060" title="DOI URL">https://doi.org/10.1016/j.ejmech.2011.05.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2011.05.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2011.05.060%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252Binsights%252Binto%252Bthe%252Bstructural%252Brequirements%252Bfor%252Bpro-apoptotic%252Bagents%252Bbased%252Bon%252B2%25252C4-diaminoquinazoline%25252C%252B2%25252C4-diaminopyrido%25255B2%25252C3-d%25255Dpyrimidine%252Band%252B2%25252C4-diaminopyrimidine%252Bderivatives%26aulast%3DFont%26aufirst%3DMar%25C3%25ADa%26date%3D2011%26volume%3D46%26issue%3D9%26spage%3D3887%26epage%3D3899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ri-Dong  Li</span>, <span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiao-Yan  Li</span>, <span class="hlFld-ContribAuthor ">Ze-Mei  Ge</span>, <span class="hlFld-ContribAuthor ">Run-Tao  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2011,</strong> <em>21 </em>
                                    (12)
                                     , 3637-3640. <a href="https://doi.org/10.1016/j.bmcl.2011.04.096" title="DOI URL">https://doi.org/10.1016/j.bmcl.2011.04.096</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2011.04.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2011.04.096%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252BEGFR%252Binhibitors%252Bprepared%252Bby%252Bcombination%252Bof%252Bdithiocarbamic%252Bacid%252Besters%252Band%252B4-anilinoquinazolines%26aulast%3DLi%26aufirst%3DRi-Dong%26date%3D2011%26volume%3D21%26issue%3D12%26spage%3D3637%26epage%3D3640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stéphanie  Kermorgant</span>, <span class="hlFld-ContribAuthor ">Jonna  Nevo</span>, <span class="hlFld-ContribAuthor ">Johanna  Ivaska</span>. </span><span class="cited-content_cbyCitation_article-title">Research Highlights. </span><span class="cited-content_cbyCitation_journal-name">Pharmacogenomics</span><span> <strong>2010,</strong> <em>11 </em>
                                    (6)
                                     , 743-746. <a href="https://doi.org/10.2217/pgs.10.78" title="DOI URL">https://doi.org/10.2217/pgs.10.78</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/pgs.10.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Fpgs.10.78%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacogenomics%26atitle%3DResearch%252BHighlights%26aulast%3DKermorgant%26aufirst%3DSt%25C3%25A9phanie%26date%3D2010%26volume%3D11%26issue%3D6%26spage%3D743%26epage%3D746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative inhibitors of EGFR tyrosine kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of novel Her-1/Her-2 dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) formamide, 170 °C; (b) SOCl<sub>2</sub>, POCl<sub>3</sub>, DMF (cat.), reflux; (c) anilines, <i>i</i>-PrOH, reflux; (d) Fe, concd HCl (cat.), 50% EtOH, reflux; (e) <i>N</i>-Boc-amino acids, EDCI, pyridine, r.t.; (f) TFA, DCM, r.t.; (g) acrylic acid, EDCI, pyridine, THF, 0 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. <sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) formamide, 170 °C; (b) SOCl<sub>2</sub>, POCl<sub>3</sub>, DMF (cat.), reflux; (c) anilines, <i>i</i>-PrOH, reflux; (d) sodium methoxide, DMSO, r.t.; (e) 2-methoxyethanol, KOTMS, DMSO, r.t.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Antitumor activity during treatment with <b>19c</b> (as HCl salt), <b>19d</b> (as mesylate), <b>3</b> (Lapatinib), or vehicle control in an A431-xenograft model in nude mice. Each compound was administered through once-daily oral treatments for 11 days from the 7th day after implantation. The used vehicle was 20% PEG400 in distilled water. Compounds <b>19c</b> (as HCl salt), <b>19d</b> (as mesylate), and <b>3</b> (Lapatinib) were administered at 3, 3, and 10 mg/kg, respectively. Initial group size was eight animals for all groups. All biological data were obtained from a single experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Body weight change during treatment with <b>19c</b> (as HCl salt), <b>19d</b> (as mesylate), <b>3</b> (Lapatinib), or the vehicle control in an A431-xenograft model in nude mice. See Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> for detailed study conditions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/medium/jm-2009-01146p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Body weight change during treatment with <b>19c</b> (as HCl salt) at higher doses (12.5, 25, and 50 mg/kg) or the vehicle control in an A431-xenograft model in nude mice. See Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> for details of study conditions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-21/jm901146p/production/images/large/jm-2009-01146p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm901146p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i45">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85063" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85063" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 26 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0ligsN6C2ckUlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ERBB receptors and cancer: the complexity of targeted inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ERBB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0ligsN6C2ckUlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DERBB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Yarden, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Untangling the ErbB signaling network</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">137</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+signaling+network"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0lihx3qfx3Up6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signaling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, C. J.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1053%2Fsonc.2002.31525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11894011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVKjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2002&pages=27-36&author=R.+S.+Herbstauthor=C.+J.+Langer&title=Epidermal+growth+factor+receptors+as+a+target+for+cancer+treatment%3A+The+emerging+role+of+IMC-C225+in+the+treatment+of+lung+and+head+and+neck+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers</span></div><div class="casAuthors">Herbst, Roy S.; Langer, Corey J.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1, Suppl. 4</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor is 1 of 4 receptors crit. to cellular proliferation, differentiation, and survival, and is widely expressed in malignant tissue, particularly in squamous cell carcinoma of the head and neck.  Expression has been assocd. with malignant progression, inhibition of apoptosis, neoplastic angiogenesis, enhanced metastatic potential, and both chemoresistance and radioresistance.  IMC-C225 is a chimeric monoclonal antibody that targets extracellular epidermal growth factor receptor; it has shown both in vitro and in vivo antitumor activity in tumor cell lines expressing epidermal growth factor receptor, including heightened radiation response in vitro in cultured human squamous cell carcinoma and enhancement of Taxane- and platinum-induced cytotoxicity in non-small cell lung cancer xenografts.  In A431 head and neck squamous cell xenografts, IMC-C225 administered both before and after radiation therapy yields a radiation enhancement factor of 3.62, attributable to both tumor necrosis and antiangiogenesis.  In phase I pharmacokinetic studies, IMC-C225 has a long half-life, lending itself to convenient weekly administration.  It has shown a favorable toxicity profile, limited primarily to allergic and dermatol. reactions, the latter characterized by a self-limited, sterile, acneiform rash.  Anaphylaxis is rare.  Std. treatment entails a loading dose of 400 mg/m2 at week 1, followed by a maintenance dose of 250 mg/m2 weekly.  An ongoing phase III international multicenter, randomized study in locally advanced squamous cell carcinoma of the head and neck is evaluating therapeutic radiation therapy, either alone or in conjunction with IMC-C225.  In a pilot trial, 6 of 9 patients with platinum-exposed squamous cell carcinoma of the head and neck exhibited objective response.  In an ongoing phase II trial in patients with stable or progressive disease on platinum-based therapy, the preliminary response rate is ∼20%, far higher than one would expect with std. salvage regimens.  The Eastern Cooperative Oncol. Group has completed a placebo-controlled phase III registration trial assessing cisplatin 100 mg/m2 every 4 wk with or without IMC-C225.  Three sep. phase II trials in non-small cell lung cancer have been launched: one trial tests IMC-C225 in combination with std. Paclitaxel/carboplatin; another integrates IMC-C225 into the Gemcitabine/carboplatin combination in treatment-naive patients; and a third trial evaluates IMC-C225 in combination with Docetaxel 75 mg/m2 every 3 wk in the second-line setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-zUXfAK2Y_bVg90H21EOLACvtfcHk0lihx3qfx3Up6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVKjsr4%253D&md5=b7e524110b0af8a59ad341741a4fb48d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1053%2Fsonc.2002.31525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fsonc.2002.31525%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DLanger%26aufirst%3DC.%2BJ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptors%2520as%2520a%2520target%2520for%2520cancer%2520treatment%253A%2520The%2520emerging%2520role%2520of%2520IMC-C225%2520in%2520the%2520treatment%2520of%2520lung%2520and%2520head%2520and%2520neck%2520cancers%26jtitle%3DSemin.%2520Oncol.%26date%3D2002%26volume%3D29%26spage%3D27%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Traxler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bold, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Reilly, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: from rational design to clinical trials</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">499</span><span class="NLM_x">–</span> <span class="NLM_lpage">512</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1002%2Fmed.1022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11607931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXotVeht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=499-512&author=P.+Traxlerauthor=G.+Boldauthor=E.+Buchdungerauthor=G.+Caravattiauthor=P.+Furetauthor=P.+Manleyauthor=T.+O%E2%80%99Reillyauthor=J.+Woodauthor=J.+Zimmermann&title=Tyrosine+kinase+inhibitors%3A+from+rational+design+to+clinical+trials"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors: From rational design to clinical trials</span></div><div class="casAuthors">Traxler, Peter; Bold, Guido; Buchdunger, Elisabeth; Caravatti, Giorgio; Furet, Pascal; Manley, Paul; O'Reilly, Terence; Wood, Jeanette; Zimmermann, Juerg</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">499-512</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Protein kinases play a crucial role in signal transduction as well as in cellular proliferation, differentiation, and various regulatory mechanisms.  The inhibition of growth related kinases, esp. Tyr kinases, might provide new therapies for diseases such as cancer.  The progress made in the crystn. of protein kinases has confirmed that the ATP-binding domain of Tyr kinases is an attractive target for drug design.  Three successful examples of drug design at Novartis using a Tyr kinase as a mol. target are described.  PK1166, a pyrrolo[2,3,-d]pyrimidine deriv., is a dual inhibitor of both the EGFR and the ErbB2 kinases.  The compd. entered clin. trials in 1999, based on its favorable pre-clin. profile: potent inhibition of EGF-mediated signalling in cells, in vivo antitumor activity in several EGFR over-expressing xenograft tumor models in nude mice, long-lasting inhibition of EGF-stimulated EGFR auto-phosphorylation in tumor tissue, good oral bioavailability in animals, and no prohibitive in vitro and in vivo toxicity findings.  The anilino-phthalazine deriv. PTK787/ZK222584 (Phase I, co-developed by Schering AG, Berlin) is a potent and selective inhibitor of both the KDR and Flt-1 kinases with interesting anti-angiogenic and pharmacokinetic properties (orally bioavailable).  STI 571 (Glivec, Gleevec), a phenylamino-pyrimidine deriv., is a potent inhibitor of the Abl Tyr kinase, which is present in 95% of patients with chronic myelogenous leukemia (CML).  The compd. specifically inhibits proliferation of v-Abl and Bcr-Abl expressing cells (including cells from CML patients) and shows anti-tumor activity as a single agent in animal models at well-tolerated doses.  Pharmacol. relevant concns. are achieved in the plasma of animals (oral administration).  Promising data from phase I and II clin. trials in CML patients (98% hematol. response rate in Phase I) support the fact that the STI571 represents a new treatment modality for CML.  In addn., potent inhibition of the PDGFR and c-Kit Tyr kinases also indicates its possible clin. use in solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4W1Gy1U-gvLVg90H21EOLACvtfcHk0lihx3qfx3Up6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXotVeht7c%253D&md5=bc5ca99f96e51da0736842df4fea841e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fmed.1022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.1022%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26aulast%3DBold%26aufirst%3DG.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DT.%26aulast%3DWood%26aufirst%3DJ.%26aulast%3DZimmermann%26aufirst%3DJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520from%2520rational%2520design%2520to%2520clinical%2520trials%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2001%26volume%3D21%26spage%3D499%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy</span> <span class="citation_source-journal">Drugs Future</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1087</span><span class="NLM_x">–</span> <span class="NLM_lpage">1092</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1358%2Fdof.2001.026.11.858717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsVyltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2001&pages=1087-1092&author=A.+A.+Adjei&title=Epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy</span></div><div class="casAuthors">Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of the Future</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1087-1092</span>CODEN:
                <span class="NLM_cas:coden">DRFUD4</span>;
        ISSN:<span class="NLM_cas:issn">0377-8282</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases are transmembrane proteins involved in signal transduction.  They propagate growth factor signals from the cell surface to intracellular processes that control crit. functions such as growth, differentiation, angiogenesis and inhibition of apoptosis.  In malignancies, these signaling pathways are often exploited to optimize tumor growth and metastasis.  One such family of receptor tyrosine kinases is the epidermal growth factor receptor (EGFR) tyrosine kinase.  These receptors are overexpressed in a wide variety of epithelial cancers and have been implicated in tumor aggressiveness.  Thus, targeting the EGFR tyrosine kinase has attracted considerable attention.  This review will summarize current preclin. and clin. knowledge of the small-mol. oral inhibitors of the EGFR tyrosine kinase, which include ZD-1839, OSI-774, CI-1033, EKB-569, PKI-166, GW-2016 and BIBX-1382.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfB_TYrS4ANrVg90H21EOLACvtfcHk0lihx3qfx3Up6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsVyltg%253D%253D&md5=1c66b23e86d02cfaa5e719f5c0fcd53e</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1358%2Fdof.2001.026.11.858717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdof.2001.026.11.858717%26sid%3Dliteratum%253Aachs%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DDrugs%2520Future%26date%3D2001%26volume%3D26%26spage%3D1087%26epage%3D1092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Renhowe, P. A.</span><span> </span><span class="NLM_article-title">Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy-clinical progress</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">214</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2002&pages=214-224&author=P.+A.+Renhowe&title=Inhibitors+of+growth+factor+receptor+kinase-dependent+signaling+pathways+in+anticancer+chemotherapy-clinical+progress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRenhowe%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520growth%2520factor%2520receptor%2520kinase-dependent%2520signaling%2520pathways%2520in%2520anticancer%2520chemotherapy-clinical%2520progress%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2002%26volume%3D5%26spage%3D214%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tullo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Averbuch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ochs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feyereislova, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaisland, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">–</span> <span class="NLM_lpage">2250</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1200%2FJCO.2002.10.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11980995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVKrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=2240-2250&author=M.+Ransonauthor=L.+A.+Hammondauthor=D.+Ferryauthor=M.+Krisauthor=A.+Tulloauthor=P.+I.+Murrayauthor=V.+Millerauthor=S.+Averbuchauthor=J.+Ochsauthor=C.+Morrisauthor=A.+Feyereislovaauthor=H.+Swaislandauthor=E.+K.+Rowinsky&title=ZD1839%2C+a+selective+oral+epidermal+growth+factor+receptor-tyrosine+kinase+inhibitor%2C+is+well+tolerated+and+active+in+patients+with+solid%2C+malignant+tumors%3A+results+of+a+phase+I+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial</span></div><div class="casAuthors">Ranson, Malcolm; Hammond, Lisa A.; Ferry, David; Kris, Mark; Tullo, Andrew; Murray, Philip I.; Miller, Vince; Averbuch, Steve; Ochs, Judy; Morris, Charles; Feyereislova, Andrea; Swaisland, Helen; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2240-2250</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.  Patients and Methods: This was an open, phase I, escalating multiple-dose tolerability and pharmacokinetic trial.  ZD1839 was administered once daily for 14 consecutive days followed by 14 days off treatment.  Dose escalation started at 50 mg/d and continued to 925 mg or until consistent dose-limiting toxicity (DLT) was obsd.  Results: Sixty-four patients were entered at eight dose levels.  The most frequent dose-related grade 1 and 2 adverse events were an acne-like (or folliculitis) rash, nausea, and diarrhea.  Three of nine patients treated at 700 mg/d developed DLT (reversible grade 3 diarrhea); grade 3 and 4 events were uncommon.  Exposure to ZD1839 was dose proportional, and the mean terminal half-life was 48 h (range, 37 to 65).  Four of 16 patients with non-small-cell lung cancer (NSCLC) had objective partial responses obsd. from ZD1839 300 to 700 mg/d.  Overall, 16 patients remained on study for ≥ 3 mo, with seven of these patients (five with NSCLC, including three of the patients with partial response) remaining on study for ≥ 6 mo.  Conclusion: ZD1839 was well tolerated, with DLT obsd. at a dose well above that at which antitumor activity was seen.  Pharmacokinetic anal. confirmed that ZD1839 was suitable for administration as a once-daily oral tablet formulation.  Phase II monotherapy and phase III combination trials in NSCLC are being conducted to investigate further the efficacy, tolerability, and optimal daily dose of ZD1839.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDgNViETgVS7Vg90H21EOLACvtfcHk0liRfqsmH25TLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVKrsrc%253D&md5=b2de082b8b9292bb6cc62e4ea0a7b166</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.10.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.10.112%26sid%3Dliteratum%253Aachs%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DHammond%26aufirst%3DL.%2BA.%26aulast%3DFerry%26aufirst%3DD.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DTullo%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DP.%2BI.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DAverbuch%26aufirst%3DS.%26aulast%3DOchs%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DFeyereislova%26aufirst%3DA.%26aulast%3DSwaisland%26aufirst%3DH.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DZD1839%252C%2520a%2520selective%2520oral%2520epidermal%2520growth%2520factor%2520receptor-tyrosine%2520kinase%2520inhibitor%252C%2520is%2520well%2520tolerated%2520and%2520active%2520in%2520patients%2520with%2520solid%252C%2520malignant%2520tumors%253A%2520results%2520of%2520a%2520phase%2520I%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D2240%26epage%3D2250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Ciardiello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tortora, G.</span><span> </span><span class="NLM_article-title">A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2958</span><span class="NLM_x">–</span> <span class="NLM_lpage">2970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=11595683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvF2ktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=2958-2970&author=F.+Ciardielloauthor=G.+Tortora&title=A+novel+approach+in+the+treatment+of+cancer%3A+Targeting+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor</span></div><div class="casAuthors">Ciardiello, Fortunato; Tortora, Giampaolo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2958-2970</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) autocrine pathway contributes to a no. of processes important to cancer development and progression, including cell proliferation, apoptosis, angiogenesis, and metastatic spread.  The crit. role the EGFR plays in cancer has led to an extensive search for selective inhibitors of the EGFR signaling pathway.  The results of a large body of preclin. studies and the early clin. trials thus far conducted suggest that targeting the EGFR could represent a significant contribution to cancer therapy.  A variety of different approaches are currently being used to target the EGFR.  The most promising strategies in clin. development include monoclonal antibodies to prevent ligand binding and small mol. inhibitors of the tyrosine kinase enzymic activity to inhibit autophosphorylation and downstream intracellular signaling.  At least five blocking monoclonal antibodies have been developed against the EGFR.  Among these, IMC-225 is a chimeric human-mouse monoclonal IgG1 antibody that has been the first anti-EGFR targeted therapy to enter clin. evaluation in cancer patients in Phase II and III studies, alone or in combination with conventional therapies, such as radiotherapy and chemotherapy.  A no. of small mol. inhibitors of the EGFR tyrosine kinase enzymic activity is also in development.  OSI-774 and ZD1839 (Iressa) are currently in Phase II and III development, resp.  ZD1839, a p.o. active, selective quinazoline deriv. has demonstrated promising in vitro and in vivo antitumor activity.  Preliminary results from Phase I and II trials in patients with advanced disease demonstrate that ZD1839 and OSI-774 have an acceptable tolerability profile and promising clin. efficacy in patients with a variety of tumor types.  This mini-review describes the EGFR inhibitors in clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWMqDAds0bV7Vg90H21EOLACvtfcHk0liRfqsmH25TLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvF2ktbk%253D&md5=b83b93c1e98ab401ae809dac422fbb3c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCiardiello%26aufirst%3DF.%26aulast%3DTortora%26aufirst%3DG.%26atitle%3DA%2520novel%2520approach%2520in%2520the%2520treatment%2520of%2520cancer%253A%2520Targeting%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D2958%26epage%3D2970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagrath, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inserra, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederichs, S.</span><span> </span><span class="NLM_article-title">Detection of mutations in EGFR in circulating lung-cancer cells</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">359</span><span class="NLM_x">, </span> <span class="NLM_fpage">366</span><span class="NLM_x">–</span> <span class="NLM_lpage">377</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1056%2FNEJMoa0800668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=18596266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFSqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=366-377&author=S.+Maheswaranauthor=L.+V.+Sequistauthor=S.+Nagrathauthor=L.+Ulkusauthor=B.+Branniganauthor=E.+Inserraauthor=S.+Diederichs&title=Detection+of+mutations+in+EGFR+in+circulating+lung-cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of mutations in EGFR in circulating lung-cancer</span></div><div class="casAuthors">Maheswaran, Shyamala; Sequist, Lecia V.; Nagrath, Sunitha; Ulkus, Lindsey; Brannigan, Brian; Collura, Chey V.; Inserra, Elizabeth; Diederichs, Sven; Iafrate, A. John; Bell, Daphne W.; Digumarthy, Subba; Muzikansky, Alona; Irimia, Daniel; Settleman, Jeffrey; Tompkins, Ronald G.; Lynch, Thomas J.; Toner, Mehmet; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">366-377</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The use of tyrosine kinase inhibitors to target the epidermal growth factor receptor gene (EGFR) in patients with non-small-cell lung cancer is effective but limited by the emergence of drug-resistance mutations.  Mol. characterization of circulating tumor cells may provide a strategy for noninvasive serial monitoring of tumor genotypes during treatment.  Methods: The authors captured highly purified circulating tumor cells from the blood of patients with non-small-cell lung cancer using a microfluidic device contg. microposts coated with antibodies against epithelial cells.  The authors performed EGFR mutational anal. on DNA recovered from circulating tumor cells using allele-specific polymerase-chain-reaction amplification and compared the results with those from concurrently isolated free plasma DNA and from the original tumor-biopsy specimens.  Results: The authors isolated circulating tumor cells from 27 patients with metastatic non-small-cell lung cancer (median no., 74 cells per mL).  The authors identified the expected EGFR activating mutation in circulating tumor cells from 11 of 12 patients (92%) and in matched free plasma DNA from 4 of 12 patients (33%) (P = 0.009).  The authors detected the T790M mutation, which confers drug resistance, in circulating tumor cells collected from patients with EGFR mutations who had received tyrosine kinase inhibitors.  When T790M was detectable in pretreatment tumor-biopsy specimens, the presence of the mutation correlated with reduced progression-free survival (7.7 mo vs. 16.5 mo, P < 0.001).  Serial anal. of circulating tumor cells showed that a redn. in the no. of captured cells was assocd. with a radiog. tumor response; an increase in the no. of cells was assocd. with tumor progression, with the emergence of addnl. EGFR mutations in some cases.  Conclusions: Mol. anal. of circulating tumor cells from the blood of patients with lung cancer offers the possibility of monitoring changes in epithelial tumor genotypes during the course of treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLTOKkqtYuf7Vg90H21EOLACvtfcHk0liRfqsmH25TLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFSqtbc%253D&md5=486f7f0595f77b80e72d508b690febf6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0800668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0800668%26sid%3Dliteratum%253Aachs%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DNagrath%26aufirst%3DS.%26aulast%3DUlkus%26aufirst%3DL.%26aulast%3DBrannigan%26aufirst%3DB.%26aulast%3DInserra%26aufirst%3DE.%26aulast%3DDiederichs%26aufirst%3DS.%26atitle%3DDetection%2520of%2520mutations%2520in%2520EGFR%2520in%2520circulating%2520lung-cancer%2520cells%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D359%26spage%3D366%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Wenle, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alligood, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spector, N. L.</span><span> </span><span class="NLM_article-title">Anti-tumor activity of GW-572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6255</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=6255-6263&author=X.+Wenleauthor=R.+J.+Mullinauthor=B.+R.+Keithauthor=L.+H.+Liuauthor=H.+Maauthor=D.+W.+Rusnakauthor=G.+Owensauthor=K.+J.+Alligoodauthor=N.+L.+Spector&title=Anti-tumor+activity+of+GW-572016%3A+A+dual+tyrosine+kinase+inhibitor+blocks+EGF+activation+of+EGFR%2FerbB2+and+downstream+Erk1%2F2+and+AKT+pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWenle%26aufirst%3DX.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DLiu%26aufirst%3DL.%2BH.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DOwens%26aufirst%3DG.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DSpector%26aufirst%3DN.%2BL.%26atitle%3DAnti-tumor%2520activity%2520of%2520GW-572016%253A%2520A%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520blocks%2520EGF%2520activation%2520of%2520EGFR%252FerbB2%2520and%2520downstream%2520Erk1%252F2%2520and%2520AKT%2520pathways%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D6255%26epage%3D6263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Johnston, S. R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leary, A.</span><span> </span><span class="NLM_article-title">Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer</span> <span class="citation_source-journal">Drugs Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">453</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1358%2Fdot.2006.42.7.985637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFamsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=441-453&author=S.+R.+D.+Johnstonauthor=A.+Leary&title=Lapatinib%3A+A+novel+EGFR%2FHER2+tyrosine+kinase+inhibitor+for+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer</span></div><div class="casAuthors">Johnston, Stephen R. D.; Leary, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of Today</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">441-453</span>CODEN:
                <span class="NLM_cas:coden">MDACAP</span>;
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Lapatinib is an oral dual tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2), both frequently overexpressed in human cancer.  Preclin. data have shown that lapatinib is a potent and selective inhibitor of the tyrosine kinase domain of EGFR and HER2, and tumor cells that overexpress these receptors are growth inhibited by lapatinib both in vitro and in vivo.  Phase I clin. trials have shown that lapatinib is well tolerated, with mild diarrhea and rash the most frequent toxicities, and early evidence of clin. efficacy has been reported esp. in HER2-pos. breast cancer.  Phase II studies have shown activity for lapatinib in trastuzumab-refractory breast cancer either alone or in combination with trastuzumab.  When used as first-line monotherapy for advanced breast cancer, objective tumor responses have been seen in 28% of patients with untreated HER2-pos. advanced breast cancer.  An extensive phase III program in advanced breast cancer is now in progress both for refractory disease and as first-line therapy in combination with chemotherapy with and without trastuzumab, and with endocrine therapy.  Phase II studies have also been conducted in a variety of other tumors, including renal cell cancer.  Parallel biomarker studies are starting to elucidate predictive mol. phenotypes that may indicate likelihood of response to lapatinib, and these may direct future trials with this oral tyrosine kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC9Obf0OXhBLVg90H21EOLACvtfcHk0ljoH0eJAyo73g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFamsLzO&md5=a1ebcf51ffa841d1fe058eebcc1e05fa</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1358%2Fdot.2006.42.7.985637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2006.42.7.985637%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26aulast%3DLeary%26aufirst%3DA.%26atitle%3DLapatinib%253A%2520A%2520novel%2520EGFR%252FHER2%2520tyrosine%2520kinase%2520inhibitor%2520for%2520cancer%26jtitle%3DDrugs%2520Today%26date%3D2006%26volume%3D42%26spage%3D441%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reigh, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3958</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=R.+Nilakantanauthor=E.+Overbeekauthor=M.+F.+Reighauthor=R.+Shenauthor=X.+Shiauthor=H.+R.+Tsouauthor=Y.+F.+Wangauthor=A.+Wissner&title=Antitumor+activity+of+HKI-272%2C+an+orally+active%2C+irreversible+inhibitor+of+the+HER-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0ljoH0eJAyo73g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReigh%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520HKI-272%252C%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520HER-2%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.</span><span> </span><span class="NLM_article-title">Synthesis and structure−activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles: The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.+Wangauthor=L.+M.+Greenbergerauthor=H.+Tsou&title=Synthesis+and+structure%E2%88%92activity+relationships+of+6%2C7-disubstituted+4-anilinoquinoline-3-carbonitriles%3A+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520structure%25E2%2588%2592activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinoline-3-carbonitriles%253A%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-<i>d</i>]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000372i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=429-440&author=J.+B.+Smaillauthor=H.+D.+H.+Showalterauthor=H.+Zhouauthor=A.+J.+Bridgesauthor=D.+J.+McNamaraauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=P.+W.+Vincentauthor=B.+J.+Robertsauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+18.+6-Substituted+4-anilinoquinazolines+and+4-anilinopyrido%5B3%2C4-d%5Dpyrimidines+as+soluble%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Fjm000372i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000372i%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252018.%25206-Substituted%25204-anilinoquinazolines%2520and%25204-anilinopyrido%255B3%252C4-d%255Dpyrimidines%2520as%2520soluble%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D429%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Campos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiden, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plante, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potkul, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldjian, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varterasian, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charbonneau, C.</span><span> </span><span class="NLM_article-title">Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5597</span><span class="NLM_x">–</span> <span class="NLM_lpage">5604</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1200%2FJCO.2005.08.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=16110019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVersr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5597-5604&author=S.+Camposauthor=O.+Hamidauthor=M.+V.+Seidenauthor=A.+Ozaauthor=M.+Planteauthor=R.+K.+Potkulauthor=P.+F.+Lenehanauthor=E.+P.+Kaldjianauthor=M.+L.+Varterasianauthor=C.+Jordanauthor=C.+Charbonneau&title=Multicenter%2C+randomized+phase+II+trial+of+oral+CI-1033+for+previously+treated+advanced+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer</span></div><div class="casAuthors">Campos, Susana; Hamid, Oday; Seiden, Michael V.; Oza, Amit; Plante, Marie; Potkul, Ronald K.; Lenehan, Peter F.; Kaldjian, Eric P.; Varterasian, Mary L.; Jordan, Cheryl; Charbonneau, Claudie; Hirte, Hal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5597-5604</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To evaluate the antitumor activity and toxicity of two doses of CI-1033 in patients with platinum-refractory or recurrent ovarian cancer, and to det. baseline expression of epidermal growth factor receptor in tumor cells.  Patients and Methods: This phase II, open-label clin. trial evaluated CI-1033 in patients with ovarian cancer who failed prior platinum-based therapy.  Two oral doses of CI-1033 were evaluated-a 50-mg and a 200-mg oral dose administered daily for 21 days in a 28-day cycle.  Patients were evaluated for tumor response and toxicity; in addn., archival baseline tumor samples were analyzed by immunohistochem. for erbB1 to erbB4 status.  Results: One hundred five eligible patients were treated.  Baseline demog. characteristics were balanced in this heavily pretreated patient population.  The median no. of prior chemotherapy regimens received was four.  The most commonly encountered drug-related adverse events for both dose arms were gastrointestinal (diarrhea, nausea, stomatitis) toxicity, asthenia, and rash.  No responses were obsd.  Stable disease was confirmed in 34% and 26% of patients in the 200-mg and 50-mg arms, resp., and 1-yr survival rates were 38.5% and 37.7%, resp.  Baseline erbB3 and erbB4 revealed the highest frequencies of expression, while erbB2 was the lowest.  Conclusion: CI-1033 did not show activity in unscreened patients with advanced ovarian cancer.  At 50 mg/d, CI-1033 had a more favorable adverse events profile than at 200 mg/d.  ErbB3 and erbB4 receptors showed the highest expression in tumor samples while erbB2 revealed the least.  There appears to be no assocn. between baseline erbB expression and disease stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQbgq5slTwJLVg90H21EOLACvtfcHk0liTZnZlaR8qgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVersr%252FL&md5=35cb9a35e064461ad1bbf3097ee09de8</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.08.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.08.091%26sid%3Dliteratum%253Aachs%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSeiden%26aufirst%3DM.%2BV.%26aulast%3DOza%26aufirst%3DA.%26aulast%3DPlante%26aufirst%3DM.%26aulast%3DPotkul%26aufirst%3DR.%2BK.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DKaldjian%26aufirst%3DE.%2BP.%26aulast%3DVarterasian%26aufirst%3DM.%2BL.%26aulast%3DJordan%26aufirst%3DC.%26aulast%3DCharbonneau%26aufirst%3DC.%26atitle%3DMulticenter%252C%2520randomized%2520phase%2520II%2520trial%2520of%2520oral%2520CI-1033%2520for%2520previously%2520treated%2520advanced%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5597%26epage%3D5604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+Janneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+Correlation+with+clinical+response+to+gefitinib+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lhDot1QNP09xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520Correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Yun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lhDot1QNP09xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm901146p&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm901146p&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm901146p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small+cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lhDot1QNP09xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small%2520cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">7096</span><span class="NLM_x">–</span> <span class="NLM_lpage">7101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=7096-7101&author=S.+Kobayashiauthor=H.+Jiauthor=Y.+Yuzaauthor=M.+Meyersonauthor=K.+K.+Wongauthor=D.+G.+Tenenauthor=B.+Halmos&title=An+alternative+inhibitor+overcomes+resistance+caused+by+a+mutation+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DAn%2520alternative%2520inhibitor%2520overcomes%2520resistance%2520caused%2520by%2520a%2520mutation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D7096%26epage%3D7101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, An irreversible pan-ERBB inhibitor, is effective in lung cancer models with <i>EGFR</i> and <i>ERBB2</i> mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.+M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.+K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+An+irreversible+pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.%2BM.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520An%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Shintani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crohin, C. C.</span><span> </span><span class="NLM_article-title">Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">4142</span><span class="NLM_x">–</span> <span class="NLM_lpage">4147</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=4142-4147&author=S.+Shintaniauthor=K.+Matsuoauthor=C.+C.+Crohin&title=Intragenic+mutation+analysis+of+the+human+epidermal+growth+factor+receptor+%28EGFR%29+gene+in+malignant+human+oral+keratinocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShintani%26aufirst%3DS.%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DCrohin%26aufirst%3DC.%2BC.%26atitle%3DIntragenic%2520mutation%2520analysis%2520of%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520gene%2520in%2520malignant%2520human%2520oral%2520keratinocytes%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D4142%26epage%3D4147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Wildenhain, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackstein, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrulis, I. L.</span><span> </span><span class="NLM_article-title">p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">883</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1990&pages=879-883&author=Y.+Wildenhainauthor=T.+Pawsonauthor=M.+E.+Blacksteinauthor=I.+L.+Andrulis&title=p185neu+is+phosphorylated+on+tyrosine+in+human+primary+breast+tumors+which+overexpress+neu%2FerbB-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWildenhain%26aufirst%3DY.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DBlackstein%26aufirst%3DM.%2BE.%26aulast%3DAndrulis%26aufirst%3DI.%2BL.%26atitle%3Dp185neu%2520is%2520phosphorylated%2520on%2520tyrosine%2520in%2520human%2520primary%2520breast%2520tumors%2520which%2520overexpress%2520neu%252FerbB-2%26jtitle%3DOncogene%26date%3D1990%26volume%3D5%26spage%3D879%26epage%3D883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">7096</span><span class="NLM_x">–</span> <span class="NLM_lpage">7101</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=7096-7101&author=S.+Kobayashiauthor=H.+Jiauthor=Y.+Yuzaauthor=M.+Meyersonauthor=K.+Wongauthor=D.+G.+Tenenauthor=B.+Halmos&title=An+alternative+inhibitor+overcomes+resistance+caused+by+a+mutation+of+the+epidermal+growth+factor+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DAn%2520alternative%2520inhibitor%2520overcomes%2520resistance%2520caused%2520by%2520a%2520mutation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D7096%26epage%3D7101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="note"><p class="first last">Inhibition rate (%) = (1 − relative tumor growth in treated group/relative tumor growth in control group) × 100.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lee, K.-O.; Gong, J. H.; Cha, M. Y.; Lee, C. G.; Kim, Y. H.; Lee, K.; Song, T. H.; Song, J. Y.; Park, Y.-J.; Kim, E. Y.; Lee, E.; Lee, K.; Kim, M. S.; Lee, G. S.</span><span> </span><span class="NLM_article-title">Quinazoline derivatives for inhibiting the growth of cancer cell</span>. PCT Int. Appl. WO2008002039A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.-O.+Lee&author=J.+H.+Gong&author=M.+Y.+Cha&author=C.+G.+Lee&author=Y.+H.+Kim&author=K.+Lee&author=T.+H.+Song&author=J.+Y.+Song&author=Y.-J.+Park&author=E.+Y.+Kim&author=E.+Lee&author=K.+Lee&author=M.+S.+Kim&author=G.+S.+Lee&title=Quinazoline+derivatives+for+inhibiting+the+growth+of+cancer+cell"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.-O.%26atitle%3DQuinazoline%2520derivatives%2520for%2520inhibiting%2520the%2520growth%2520of%2520cancer%2520cell%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ham, Y. J.; Gong, J. H.; Cha, M. Y.; Kim, J. W.; Kim, M. S.; Kim, E. Y.; Song, J. Y.; Kim, C. I.; Kim, S. Y.; Lee, G. S.</span><span> </span><span class="NLM_article-title">Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof</span>. PCT Int. Appl. WO2006071017A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=Y.+J.+Ham&author=J.+H.+Gong&author=M.+Y.+Cha&author=J.+W.+Kim&author=M.+S.+Kim&author=E.+Y.+Kim&author=J.+Y.+Song&author=C.+I.+Kim&author=S.+Y.+Kim&author=G.+S.+Lee&title=Quinazoline+derivatives+for+inhibiting+cancer+cell+growth+and+method+for+the+preparation+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHam%26aufirst%3DY.%2BJ.%26atitle%3DQuinazoline%2520derivatives%2520for%2520inhibiting%2520cancer%2520cell%2520growth%2520and%2520method%2520for%2520the%2520preparation%2520thereof%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Gong, J. H.; Cha, M. Y.; Kim, J. W.; Lee, C. G.; Kim, S. Y.; Lee, K.-O.; Kim, M. S.; Kim, H. K.; Lim, C. K.; Kim, Y. H.; Lee, G. S.</span><span> </span><span class="NLM_article-title">Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof</span>. PCT Int. Appl. WO2006071079A1,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=J.+H.+Gong&author=M.+Y.+Cha&author=J.+W.+Kim&author=C.+G.+Lee&author=S.+Y.+Kim&author=K.-O.+Lee&author=M.+S.+Kim&author=H.+K.+Kim&author=C.+K.+Lim&author=Y.+H.+Kim&author=G.+S.+Lee&title=Quinazoline+derivatives+for+inhibiting+cancer+cell+growth+and+method+for+the+preparation+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%2BH.%26atitle%3DQuinazoline%2520derivatives%2520for%2520inhibiting%2520cancer%2520cell%2520growth%2520and%2520method%2520for%2520the%2520preparation%2520thereof%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="note"><p class="first last">A431 cell washout test. A431 cells were incubated in 6-well plates to the extent of 500000 cells/well for 24 h. One set of cells were treated with 1 μM of <b>2</b> (Erlotinib) and the other set of cells were treated with 1 μM of analog <b>19c</b> for 4 h. Each set was washed four times with warmed compound-free medium and incubated for 8 h. Each set was simulated with EGF (100 ng/mL) for 5 min. The phosphorylation rate of EGFR was measured by Western blot. From this experiment, compound <b>19c</b> showed significant less phosphorylation rate (15%) of EGFR than <b>2</b> (100% phosphorylation). This result suggests that compound <b>19c</b> has an irreversible binding mode.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last"><i>V</i> = <i>L</i> × <i>S</i><sup>2</sup>/2 (<i>V</i>, tumor volume in milligrams; <i>L</i>, long diameter; <i>S</i>, short diameter).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i44"><a href="/doi/suppl/10.1021/jm901146p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_38146"></div></div></div></div></div><hr /></hr><p class="last"><sup>1</sup>H NMR, <sup>13</sup>C NMR, and in vivo efficacy data for our leading compounds (<b>19c</b> and <b>19d</b>). This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm901146p/suppl_file/jm901146p_si_001.pdf">jm901146p_si_001.pdf (263.69 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm901146p&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Fjm901146p%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2009.52.issue-21%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm901146p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6647e9181943","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
